An Open-Label, Single-Arm Study of ATG-010 Plus Dexamethasone in Patients With Multiple Myeloma Refractory to Prior Treatment With Immunomodulatory Agents and Proteasome Inhibitor
Phase: PHASE2
Conditions: Relapse/Refractory Multiple Myeloma
Sponsor: Antengene Corporation

 
 
 
 
  
 
 
 
 
 
 
 
 
 
Clinical Trial Protocol 
 
 
 
 
 
 
 
Confidentiality Information 
This clinical trial protocol belongs to the proprietary confidential information of 
Zhejiang Antengene Pharmaceuticals Co., Ltd. and shall not be used, disclosed, or 
published without consent. 
 
 
 
 
Product Name: 
ATG-010 (Selinexor) 
Study Protocol No: 
ATG-010-MM-001 
Protocol Title: 
An Open-Label, Single-Arm Clinical Study of ATG-010 Plus 
Low-Dose Dexamethasone in Patients with 
Relapsed/Refractory Multiple Myeloma Previously Treated 
with Immunomodulatory Agent and Proteasome Inhibitor 
Protocol date: 
January 2, 2020 Version 4.0 
In lieu of Protocol 
Version Date: 
March 1, 2019 Version 3.0 
IND Number: 
Not applicable. 
Sponsor 
Name/Address: 
Zhejiang Antengene Pharmaceuticals Co., Ltd. 
Room 315, Building 4, Life Science Industrial Park, 398 
Mahuan Road, Lihai Town, Binhai New City, Shaoxing, 
Zhejiang Province, P.R. China 

ATG-010-MM-001 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
2/77 
 
 
 
Medical Personnel/Emergency Contact Information 
Medical Personnel: 
Name: Jiao Ying 
Position: Associate Director, Clinical R&D Department 
Tel: +86 10 6526 1838 
E-mail: Judy.jiao@antengene.com 
 
Project management personnel: 
Name: Hua Xiang 
Title: Senior Project Manager 
Tel: +86 21 3250 1095 
Email: eric.hua@antengene.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ATG-010-MM-001 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
3/77 
 
 
 
 
Signature Page of the Protocol 
 
 
Signature of Chief Executive Officer, Zhejiang Antengene 
Pharmaceuticals Co., Ltd. 
month/day/year 
 Jay Mei 
Printed Name of Chief Executive Officer, Zhejiang Antengene Pharmaceuticals Co., Ltd. 
I sign here to indicate that I have reviewed and confirmed this study protocol and accept 
the contents of the study. 
 
 
 
 
Signature of Chief Statistician, Zhejiang Antengene 
Pharmaceuticals Co., Ltd. 
month/day/year 
 Yang Yijun 
Printed Name of Chief Statistician, Zhejiang Antengene Pharmaceuticals Co., Ltd. 
I sign here to indicate that I have reviewed and confirmed this study protocol and accept 
the contents of the study. 
 
 
 
 
 

ATG-010-MM-001 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
4/77 
 
 
Study Site Principal Investigator Signature Page 
 
 
Signature of Study Site Principal Investigator 
 
month/day/year 
Printed Name of Study Site Principal Investigator 
Organization Name:  
 
By signing here I agree to personally supervise the conduct of this study in the study site 
and ensure that the study is conducted in accordance with the following requirements: 
study protocol, informed consent form, Institutional Review Board (IRB)/Ethics 
Committee (EC) procedures, instructions from Antengene corporation representative, 
Declaration of Helsinki, International Conference on Harmonisation (ICH) guidelines 
on Good Clinical Practice (GCP), and local regulations on the conduct of clinical studies. 
 
 
 

ATG-010-MM-001 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
5/77 
 
Protocol Synopsis 
Study Title: 
An Open-Label, Single-Arm Clinical Study of ATG-010 Plus Low-Dose Dexamethasone in Patients 
with Relapsed/Refractory Multiple Myeloma Previously Treated with Immunomodulatory Agent and 
Proteasome Inhibitor 
Indication 
Relapsed/Refractory Multiple Myeloma Previously Treated with Immunomodulatory Agent and 
Proteasome Inhibitor 
Objectives: 
Primary Objective: 
To evaluate the overall response rate (ORR) for treatment with ATG-010 plus low-dose 
dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with 
immunomodulatory agent and proteasome inhibitor 
Secondary Objectives:  
To evaluate the following endpoints of ATG-010 in the study: 
a. Efficacy 
 
Survival rate (SR) at 6 months, 9 months, and 12 months 
 
Time to Progression (TTP) 
 
Progression Free Survival (PFS) 
 
Duration of response (DOR) 
 
Clinical Benefit Rate (CBR) 
 
Disease Control Rate (DCR) 
 
Overall Survival (OS) 
 
Minimal Residual Disease (MRD) 
 
The effect of risk factor stratification on clinical efficacy 
 b. Safety and tolerability  
 c. Pharmacokinetics (PK) parameters 
Background and Study Design Rationale 
Background 
Multiple myeloma (MM) is the second most common hematological malignancy (after 
non-Hodgkin’s lymphoma), representing 1% of all cancers and 2% of all cancer deaths. According 
to the literature, the reported annual incidence of MM in the United States (US) and the European 
Union (EU) is 4.5-7/100,000. Although MM is currently not a common hematological malignancy in 
Asia, the incidence is rapidly increasing. In China, according to the previous epidemiology study 
results, the incidence of MM was 0.6/100,000 in 2005. The mortality rate of MM in China was 
0.6/100,000 in 2013. In addition, another large-scale retrospective study of MM patient in China 
indicated that Chinese patients were often at an advanced stage with more serious renal dysfunctions 
and bone destructions at the time of diagnosis compared to patients in Western countries.  
In the past 20 years, new therapies, such as proteasome inhibitors (PI) and immunomodulatory 
agents (IMiD), have significantly improved the survival rate of MM patients. Despite the increased 
effectiveness of variety agents in clinical practice, nearly all MM patients will eventually become 

ATG-010-MM-001 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
6/77 
 
refractory to the treatment or relapse with their diseases; and their disease characteristics 
obviouslypresent as drug resistance and disease progression. Therefore, there is an unmet medical 
need for therapies in patients with relapsed and/or refractory (RR) MM. 
Study design rationale 
ATG-010 (Selinexor) is an orally bioavailable, selective inhibitor of nuclear export (SINE) 
compound that specifically blocks exportin 1 (XPO1). In preclinical studies, ATG-010 and other 
SINE compounds have demonstrated anti-MM activity. The completed Phase 1 clinical study, single 
agent ATG-010 showed an overall response rate (ORR) of 5%, while the ORR was 32% in 
combination with low‑dose dexamethasone. In a Phase 2b clinical study (Part 1 of STORM study), 
the clinical efficacy and safety of ATG-010 80 mg plus dexamethasone 20 mg orally twice weekly 
were evaluated in patients with RRMM. The target population had either quad-relapsed/refractory 
MM (patients who have received bortezomib, carfilzomib, lenalidomide, and pomalidomide before 
enrollment) or penta-relapsed/refractory MM (patients who have received bortezomib, carfilzomib, 
lenalidomide, pomalidomide, and anti-CD38 monoclonal antibodies before enrollment were 
refractory to treatment and relapsed before enrollment). The primary endpoint for this study was 
ORR to validate the efficacy of the ATG-010 in these patients with polylines of relapsed/refractory 
disease. The preliminary results for this Phase 2b study indicated an ORR of 25.4% in the target 
population. Relevant results show that the efficacy of ATG-010 combined with low-dose 
dexamethasone is encouraging in patients with RRMM who had previously received polyline 
therapies and had limited treatment options. 
Based on the promising efficacy data observed from the STORM study in Western population of 
RRMM, the current study is planned to extend ATG-010 combined with low-dose dexamethasone 
to the treatment of RRMM patients in China, in order to validate the clinical efficacy and safety of 
ATG-010 in Chinese RRMM patients. 
Study Design 
This is a single-arm and open-label study. Approximately 82 patients will be enrolled in the study. 
The treatment regimen is ATG-010 80 mg plus dexamethasone 20 mg by oral, twice per week, 
4 weeks per cycle. Clinical efficacy, safety and tolerability of ATG-010 will be evaluated. Blood 
samples from the 15 patients of enrolled will be collected for additional PK analysis. 
Study Population 
Inclusion Criteria: 
Patients must meet all of the following inclusion criteria to be eligible to enroll in this study: 
1. Aware and sign the informed consent form (ICF) voluntarily. 
2. Age ≥ 18 years. 
3. Patients with multiple myeloma must have previously received regimens with 
immunomodulatory agent (lenalidomide) and proteasome inhibitor (bortezomib), are refractory 
to both drugs, and are refractory or intolerant to the most recent line of therapy (Patients 
documented as intolerant are allowed to be screened only after discussing and obtaining an 
approval from Sponsor Medical Monitor). Refractory MM includes primary refractory (patients 
do not achieve minimal response (MR) or have disease progression during therapy) or 
secondary refractory patients have progression within 60 days after completion of therapy). 

ATG-010-MM-001 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
7/77 
 
4. Any non-hematological toxicities (except for peripheral neuropathy as described in exclusion 
criterion #17) that are relevant to previous therapies must have resolved to ≤ Grade 2 prior to 
the first dose of study drug. 
5. Adequate hepatic function: total bilirubin <2× upper limit of normal (ULN) (for patients with 
Gilbert’s syndrome, a total bilirubin of <3× ULN is required), AST <2.5× ULN, and ALT <2.5× 
ULN. 
6. Adequate renal function: estimated creatinine clearance ≥20 mL/min (calculated using the 
formula of Cockroft-Gault). 
7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2. 
8. Measurable MM as defined by at least one of the following: 
a． Serum M-protein (by serum protein electrophoresis, SPEP) ≥5 g/L,  
b．24 hours-Urinary M-protein excretion ≥0.2 g (200 mg), 
c． Serum free light chain (FLC) ≥100 mg/L with abnormal FLC ratio.  
9. Adequate hematopoietic function (no platelet transfusions within 1 week, and no red blood cell 
transfusions within 2 weeks prior to screening examination): 
a． Hemoglobin level ≥80 g/L 
b．ANC ≥1000/mm3 (1.0×10 9/L)   
c． Percentage of plasma cells in bone marrow <50%, platelet count ≥75,000/mm3 (75×10 9/L); 
or percentage of plasma cells in bone marrow ≥50%, platelet count ≥50,000/mm3 (50×10 9/L). 
10. Female patients of childbearing potential must meet below two criteria: 
a. 
Female patients of childbearing potential must agree to use 2 methods of contraception 
acceptable by the study physician or complete sexual abstinence throughout the study, and 
for 3 months following the last dose of study treatment. 
i. 
Sexual abstinence: this method is acceptable when it is consistent with the patient’s 
preference and daily lifestyle. Periodic abstinence (based on calendar, ovulation, 
symotmatic body temperature, or post-ovulation methods) is not acceptable. 
ii. 
Acceptable contraception methods include: oral contraceptives, injectable 
contraceptives, 
or 
implanted 
sex 
hormonal 
contraceptives, 
intrauterine 
contraceptive device, barrier contraceptivse with spermicide; or a sexual partner 
who is status post of a sterilization surgery and using at least one barrier 
contraceptive tool. 
b. Must have a negative serum pregnancy test at screening.  
Note: Female patients of childbearing potential refer to all women who have started 
menarche and are not in the postmenopausal period and have not had surgical sterilization 
(for example hysterectomy, bilateral salpingectomy, and bilateral oophorectomy). 
Postmenopausal is defined as more than 12 consecutive months of amenorrhea for 
unspecified reasons. Women who are taking oral contraceptives or using mechanical 
contraceptive method such as intrauterine device are considered childbearing potential. 
11. Male patients (including those who have received vasectomy) must agree to use a condom if 
sexually active with a female of child-bearing potential from the date of signing the informed 
consent form (ICF), throughout the study, and for 3 months without pregnancy plan following 
the last dose of study treatment. 
Exclusion Criteria: 

ATG-010-MM-001 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
8/77 
 
Patients who meet any of the following criteria will not be enrolled: 
1. Asymptomatic (smoldering) MM. 
2. Plasma cell leukemia. 
3. Documented complicated with amyloidosis. 
4. Central nervous system (CNS) involved MM. 
5. Pregnancy or breastfeeding. 
6. Prior to the first dose of study drug: 
a． Chemotherapy within 1 week (including steroid therapy in chemotherapy regimen); 
b．Radiation, immunotherapy or other anti-MM therapy within 4 weeks; 
c． Radio-immunotherapy within 6 weeks. 
7. Graft versus host disease (after allogeneic stem cell transplantation). 
8. Life expectancy of < 4 months. 
9. Major surgery within 4 weeks prior to the first dose of study drug. 
10. Patients with active, unstable cardiovascular diseases, meet any of the following: 
a. Symptomatic ischemia;  
b. Uncontrolled clinically-significant conduction abnormalities (e.g., patients with ventricular 
tachycardia on antiarrhythmics are excluded; patients with first-degree atrioventricular (AV) 
block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) 
are allowed); 
c. Congestive heart failure (CHF) of New York Heart Association (NYHA) ≥ Grade 3; 
d. Acute myocardial infarction (AMI) within 3 months prior to the first dose of study drug. 
11. Uncontrolled hypertension (systolic blood pressure >140 mmHg or diastolic blood pressure >90 
mmHg). 
12. Uncontrolled active infection requiring treatment within 1 week prior to the first dose of study 
drug. 
13. Known HIV seropositive. 
14. Known active hepatitis A, B, or C infection; or known to be positive for HCV RNA or HBsAg 
(HBV surface antigen). 
Note: including HBsAg negative but hepatitis B cored (HBc) antibody positive with detectable 
hepatitis B virus deoxyribonucleic acid (HBV-DNA) level (the upper limit of normal for 
HBV-DNA testing is based on the test value of each center). 
15. Prior malignancy that required treatment or has shown evidence of recurrence (except for skin 
basal-cell carcinoma and the following in-situ carcinoma: squamous cell carcinoma, bladder 
cancer in situ, endometrial cancer in situ, cervical cancer in situ/atypical hyperplasia, 
accidental histological finding of prostate cancer (TNM staging is T1a or T1b), or breast cancer 
in situ) within 5 years prior to the first dose of study drug. 
16. Active GI dysfunction interfering with the ability to swallow tablets, or any GI dysfunction that 
could interfere with absorption of study treatment. 
17. Grade ≥3 peripheral neuropathy, and Grade ≥2 painful neuropathy, within 3 weeks prior to the 
first dose of study drug. 
18. Active psychiatric disorder, or organic disease which, in the opinion of the Investigator, is not 
suitable for the study. 
19. Participation in another investigational anti-cancer clinical trial within 3 weeks or within 5 

ATG-010-MM-001 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
9/77 
 
half-life (T1/2) time periods prior to the first dose of study drug. 
20. Receipt any following treatments prior to the first dose of study drug: 
a. Platelet infusion within 1 week; 
b. RBC transfusion within 2 weeks; 
c. Receipt of the following blood growth factors within 2 weeks: Granulocyte colony 
stimulating factor (G-CSF), granulocyte‑macrophage colony stimulating factor (GM-CSF), 
erythropoietin (EPO), megakaryocyte growth factor, and/or platelet stimulating factor. 
21. Known intolerance to or contraindication for glucocorticoid therapy. 
22. Prior exposure to a SINE compound, including ATG-010. 
Study Duration 
The enrollment period for this study is expected to be approximately 6 months. The study will end 
when all patients have completed 12 months of treatment visit/follow-up from the initiation of the 
study drug, or when the last patient has expired, has been lost to follow-up, or has withdrawn consent, 
whichever occurs first. After the completion of this study, the Sponsor will continue providing 
ATG-010 to patients with clinical benefits (per Investigators’ judgment) as needed, and continue 
collecting actively reported safety data. 
Study Drug, Dose and Administration: 
ATG-010 will be given by oral administration at a fixed dose of 80 mg in combination with 
dexamethasone (20 mg) twice weekly for 4-week cycles. Try to take the medicine twice a week at a 
fixed time with dose interval of 48 hours (e.g., Monday and Wednesday or Tuesday and Thursday, 
etc). Dexamethasone 20 mg will be given with each dose of ATG-010. If some patients cannot tolerate 
dexamethasone 20 mg orally, the Investigator may decide to adjust the dexamethasone to a minimum 
of 10 mg for each dose in these patients. If patients still cannot tolerate this dose, a potential 
discontinuation or further dose reduction may be allowed by the Investigator after a discussion with 
the Sponsor’s Medical Monitor. Dose modification of ATG-010 can be conducted based upon grade 
severity of the adverse events (AE) as per CTCAE version 4.03. If a patient experiences more than 
one AE, dose modification will be conducted based on the AE of highest severity. If drug-related 
toxicity requires a treatment delay of more than 28 days, the patient will be withdrawn from the study 
treatment. All dose modifications or treatment delays must be documented in the electronic case 
reporting form (eCRF) and reasons must be provided. 
Concomitant medications 
To minimize nausea, unless contraindicated, all patients should receive 5‑hydroxytryptamine (5-HT3) 
antagonists (e.g., palonosetron or equivalent) before the first dose of ATG-010, and the specific 
medication frequency should be adjusted according to the actual symptoms of the patients. Alternative 
anti-emetic agents may be used if the patient does not tolerate 5-HT3 antagonists. Additional 
anti-nausea and anti-anorexia agents may be given as needed (per National Comprehensive Cancer 
Network® [NCCN] Clinical Practice Guidelines® for Antiemesis, NCCN Clinical Practice 
Guidelines® for Palliative Care and Chinese Expert Consensus on Prevention and Treatment of 
Nausea and Vomiting Related to Anti-Cancer Drug Treatment ［2019 version］). Patients will also 
receive therapy as needed to mitigate ATG-010 side effects, as part of the best supportive care. 
Blood product transfusions, antimicrobials, and growth factors including granulocyte 

ATG-010-MM-001 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
10/77 
 
colony-stimulating factors (for neutropenia), erythropoietins (for anemia), and/or platelet-stimulating 
factors for (thrombocytopenia) as the best supportive care are also permitted. 
Concurrent therapy with any other approved or investigational anti-cancer therapy is not allowed 
during study period. Patients are not allowed to participate in other clinical trials during the study. 
Study Endpoints 
Primary endpoint 
Overall response rate (ORR): Proportion of patients who achieve stringent complete response (sCR), 
complete response (CR), very good partial response (VGPR), partial response (PR).  
Secondary endpoints 
a. Efficacy: 
 
Survival rate (SR) at 6 months, 9 months, and 12 months 
 
Time to progression (TTP): Duration from start of study treatment to time of disease 
progression 
 
Progression-free survival (PFS): Duration from start of study treatment to PD or death 
(regardless of cause), whichever comes first 
 
Duration of response (DOR): Duration from the first observation of at least PR to time of 
disease progression, or deaths due to disease progression, whichever occurs first 
 
CBR: Proportion of patients who achieve sCR, CR, VGPR, PR, or minimal response (MR) 
 
DCR: Proportion of patients who achieve sCR, CR, VGPR, PR, MR, or stable disease (SD; 
for a minimum of 12 weeks) 
 
OS (Kaplan-Meier estimatess) 
 
MRD in patients who achieve CR and sCR 
 
The effect of risk factors stratification based on fluorescence in situ hybridization (FISH) on 
clinical efficacy, including del 13, del 17p13, t(4;14), t(14;16), 1q21 amplification 
b. Safety and tolerability  
c. PK: including but not limited to ATG-010 Cmax and tmax 
Criteria for Treatment Discontinuation: 
At the discretion of the Investigator, patient study treatment could be discontinued for any of 
the following reasons and the Investigator will make the decision after timely communication 
with the clinical trial monitor under specific circumstances: 
• Disease progression, 
• Intolerable AE(s), 
• Patient decides to discontinue study therapy or withdraws consent, 
• Inappropriate to continue study participation by the Investigator or significant protocol violation 
in the opinion of Investigator and Medical Monitor. 
Patients may decide to discontinue study treatment for any reason. Patients who elect to discontinue 
study treatment should be encouraged to continue in the study by Investigator so that the follow-up 
information on disease progression and survival status may be obtained. However, patients may elect 
to withdraw consent and decline further participation in the study. In this situation, the reason for 
discontinuation should be clearly documented by Investigator. Supportive clinical data are required 
when disease progression is confirmed. If the patient is removed from the study by request from 
Investigator, the reason for withdrawal should also be documented. 

ATG-010-MM-001 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
11/77 
 
Statistical Summary 
Primary analysis (including efficacy, safety, and PK) will be conducted at 3 months after the last 
patient enrollment. Supplementary efficacy and safety analysis will be conducted after the completion 
of the study. 
An interim analysis will be performed when approximately 50 patients have completed the clinical 
efficacy evaluations to assess the distribution of the patients who had previously received RRMM 
treatment. During interim analysis, the clinical efficacy in patients who had previously received 
3 types of drugs (at least an immunomodulatory [i.e., lenalidomide], at least a protease inhibitor [i.e., 
bortezomib], and at least an anti-CD38 antibody) should be analyzed, but the efficacy of whole 
population enrolled will not be analyzed. 
Sample Size Justification 
This is a bridging study. A sample size of 82 patients will allow 80% power to detect a statistical 
significance with the target ORR of 28% against the threshold ORR of 15% (one-sided α=0.025). 
Efficacy Evaluation 
The primary efficacy analysis will be based on the ORR (proportion of patients who achieve sCR, 
CR, VGPR, or PR) as assessed by an independent review committee (IRC) using the modified 
intent-to-treat (mITT) population, defined as patients who receive at least 1 dose of study treatment. 
Supportive analysis of ORR will be performed using the per‑protocol (PP) population.  
A PP population will consist of all patients in the mITT population who meet the following criteria: 
• Have ATG-010 dosing compliance ≥ 70%, 
• Have at least 1 complete post-baseline response assessment unless death or study withdrawal 
from the clinical trial, 
• No major protocol violations that would compromise the assessment of efficacy. The list of 
major protocol violations that affect statistical analysis will be finalized before database lock. 
Secondary efficacy endpoints include: PFS, TTP, CBR, DOR, etc. They will be assessed using the 
mITT and PP population. Time to failure event with censored value (including PFS, TTP, DOR) will 
be assessed for overall survival using Kaplan-Meier methods. The 95% confidence interval will be 
provided for ORR and CBR. 
PK evaluation 
The pharmacokinetic parameters of ATG-010 will be calculated from the plasma concentration data 
with non-compartment model. Descriptive statistics will be provided for all concentration data and 
PK parameters. 
Safety Evaluation 
Data from all patients who take at least one dose of study drug will be used for safety analysis of 
study drug. All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). 
AEs will be graded by CTCAE version 4.03 and AE frequency will be tabulated by MedDRA term 
and system organ class. 
A patient that experiences the same AE more than once will be counted only once. Other safety 
assessments such as hematology and chemistry will also be analyzed in the safety population.

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
 12/84 
 
 
Table 1:  Schedule of Assessments and Study Activities 
Activity/Assessment 
Screening 
Cycle 1 
Cycle 2 
Cycles ≥ 3 
End-of-
Treatment 
(EoT) Visit 
Safety 
Follow-up 
Call 
Survival 
Follow-
up15 
Day -21 
to Day -1 
Day 1 Day 3 Day 8 Day 15 Day 22 
Day 1 
Day 8 
Day 15 
Day 22 
Day 1 
≤ 14 Days Post 
Last Dose 
30 Days 
Post Last 
Dose 
Every 3 
moths 
-1 
days + 1 days ± 1 
days 
± 1 
days ± 1 days  
± 2 days  
± 2 days  ± 2 days  ± 2 days  
± 2 days  
+ 7 days 
± 14 days  
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion/exclusion criteria 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history1 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Patient height 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient weight 
X 
X 
 
X 
X 
 
X 
 
X 
 
X 
X 
 
 
Physical examination, including 
vital signs2 
X 
X 
 
X 
X 
 
X 
 
X 
 
X 
X 
 
 
ECOG scoring3 
X 
 
 
 
 
X 
 
 
 
X 
X 
 
 
Echocardiogram or MUGA3 
X 
 
 
 
 
 
 
 
 
 
 
 
 
12 Lead ECG3 
X 
 
 
 
 
 
 
 
 
 
X 
 
 
Clinical Laboratory 
Urinalysis3 
X 
 
 
 
 
 
 
 
 
 
X 
 
 
Hematology3 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
TSH3 
X 
 
 
 
 
 
 
 
 
 
X 
 
 
Complete serum chemistry3 
X 
 
 
 
 
X 
 
 
 
X 
X 
 
 
Limited serum chemistry 
 
 
X 
X 
 
 
 
X 
 
 
 
 
 
 Coagulation tests3 
X 
 
 
 
 
 
 
 
 
 
X 
 
 
HBV, HCV, HIV4 
X 
 
 
 
 
 
（X） 
 
 
 
（X） 
 
 
 
Serum hCG pregnancy test5 
X 
 
 
 
 
 
X 
(D1 of each cycle 
only) 
 
 
 
X 
(D1 of each cycle 
only) 
X 
 
 
C-reactive protein 
X 
 
 
 
 
X 
 
 
 
X 
X 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
 13/84 
 
 
Table 1:  Schedule of Assessments and Study Activities (Continued) 
Activity/Assessment 
Screening 
Cycle 1 
Cycle 2 
Cycles ≥ 3 
End-of-
Treatment (EoT) 
Visit 14 
Safety 
Follow-up 
Call 
Survival 
Follow-up15 
Day -21 to 
Day -1 
Day 1 Day 3 Day 8 
Day 15 
Day 22 
Day 1 
Day 8 
Day 15 
Day 22 
Day 1 
≤ 14 Days Post 
Last Dose  
30 Days 
Post Last 
Dose 
Every 3 
moths 
-1 days + 1 
days 
± 1 
days 
± 1 days  
± 1 days  ± 2 days  
± 2 days 
± 2 days  ± 2 days  
± 2 days  
+ 7 days 
± 14 days  
Multiple Myeloma Assessments 
SPEP and serum protein 
immunofixation 6 
X 
X 
 
 
 
 
X 
 
 
 
X 
X 
 
X 
UPEP (24-hr urine for 
total protein) and urine 
protein immunofixation6 
X 
X 
 
 
 
 
X 
 
 
 
 
X 
X 
 
X 
Quantitative Ig levels6 
X 
X 
 
 
 
 
X 
 
 
 
X 
X 
 
X 
Serum FLC6 
X 
X 
 
 
X 
 
X 
 
X 
 
X 
X 
 
X 
β2-microglobulin 
X 
 
 
 
 
 
 
 
 
 
 
X 
 
 
Skeletal survey7 
X 
 
 
 
 
 
(X) 
 
 
 
(X) 
X 
 
(X) 
Plasmacytoma 
assessment8 
X 
 
 
 
 
 
(X) 
 
 
 
(X) 
X 
 
(X) 
Bone marrow aspirate9 
X 
 
 
 
 
 
(X) 
 
 
 
(X) 
 
 
(X) 
Bone marrow biopsy10 
 
 
 
 
 
 
(X) 
 
 
 
（X） 
 
 
 
Myeloma Assessment 
X 
 
 
 
 
X 
 
 
 
X 
X 
 
（X） 
PK Sampling11 
 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
Study drug dosing 
ATG-010 80 mg + dexamethasone 20 mg (both twice weekly), oral, 4-week a cycle 
Adverse events12 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Concomitant 
medications 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Telephone contact13 
 
 
X 
 
 
 
 
 
 
 
 
 
X 
X 
Antineoplastic 
therapy 
after EoT 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
X 
 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
 14/84 
 
 
(X) indicates that additional information is provided in the footnotes. Merged cells indicate that the procedure may be performed during either Screening or C1D1 visit 
prior the first dose of study drug. 
Abbreviations: sCR = stringent complete response; CR= complete response; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; EoT = End of 
Treatment; Ig = immunoglobulin; MM = multiple myeloma; MRD= minimal residual disease; SPEP = serum protein electrophoresis; UPEP = urine protein electrophoresis; 
CBC = complete blood count; FLC = free light chain. 
1 Including details of all prior anti-myeloma therapies. Includes baseline symptoms as well as a detailed history of prior cancer therapies, especially MM therapies, 
including start and stop dates, disease progression during or after therapy, as well as discontinuations due to intolerability or any other serious illness. 
2 Complete physical examination (PE) during Screening and EoT visit. Limited PEs during the study should be symptom directed. All PEs include vital signs (blood 
pressure, pulse, respiratory rate, and body temperature). 
3 The following procedures may be performed at Screening or prior the first dose of study drug on C1D1 visit and as shown in the Schedule during the study: ECOG score, 
echocardiogram or MUGA scan, 12‑lead ECG, urinalysis, hematological tests, TSH, complete serum chemistry, coagulations tests, and infectious disease tests. ECG 
should be performed whenever there are clinical indications. 
Hematology labs: Weekly for Cycles 1-2. During Cycle 1, hematology labs will be performed at each study site on Days 1, 8, and 15, and locally on Day 22; during Cycle 
2, hematology labs will be performed at each study site on Days 1 and 15, and locally on Days 8 and 22. If the screening hematology test is performed within 5 days prior 
to Cycle 1 Day 1, it does not need to be repeated on Cycle 1 Day 1. If hematology test is required on Cycle 1 Day 1, it should be clarified that this hematology test result 
meets the protocol inclusion criteria before the first dose. 
4 Viral serology is performed at Screening, including HBsAg, HBsAb, HBcAb, HBV-DNA (eg, negative for HBsAg and positive for HBcAb), HCVAb, HCV-RNA (eg, 
positive for HCVAb), and HIV. If HBsAg is negative but anti-HBc is positive at screening, HBV-DNA must be tested and then repeated once every subsequent cycle 
(i.e., every 4 weeks). 
5 For females of childbearing potential; negative serum hCG pregnancy test must be obtained within 3 days before the first dose of study treatment. Pregnancy testing 
(serum hCG or urine) is also required for females of childbearing potential prior to dosing on Day 1 of Cycles ≥ 2 and at the EoT Visit (serum hCG). Pregnancy testing 
may also be performed as clinically indicated during the study. 
6 Response criteria include SPEP, UPEP, serum and urine immunofixation, quantitative Ig levels, and serum FLC assay on C1D1 and must be taken on prior of the first 
dose of study drug. The assessments must be repeated on the first day of following cycle, at the time of disease progression or suspected response in order to confirm 
response. Note: For patients who achieve CR or sCR, as assessed by the local laboratory, portions of collected samples will be shipped to the central laboratory for further 
confirmation. 
7 Skeletal survey to be performed using x-rays per institutional guidelines. If x-rays are used, they should include a lateral radiograph of skull, anteroposterior and lateral 
views of the spine, and anteroposterior views of the pelvis, ribs, femora, and humeri. If clinically appropriate, MRI, CT, or PET/CT, with tumor measurements, may be 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
 15/84 
 
 
used instead of, or in addition to, x-rays. If bone lesions or plasmacytomas are observed at baseline, their number and size should be recorded in the CRF. Bone lesions 
and/or plasmacytomas seen at baseline using imaging should be assessed as clinically appropriate per Investigator’s discretion during the study. Skeletal survey results 
will be judged by the radiologist at the local laboratory. 
8 If plasmacytomas are detected at baseline by PE, they should be measured and recorded, and re-assessed during the PE on Day 1 of each cycle, EoT visit, and every 3 
months (if clinically appropriate) during follow-up. 
9 Bone marrow aspirates: 
a. 
At Screening for karyotyping and FISH analysis to confirm diagnosis and classify MM sub-type (required per standard of care). 
b. MRD analysis at response for CR, sCR, or potential CR in patients with FLC only or unequivocal immunofixation electrophoresis (IFE). 
c. 
Efficacy assessment is performed according to the guidelines of the International Myeloma Working Group (IMWG). 
10 Bone marrow biopsies: 
a. 
Validation of CR and sCR by the central laboratory in accordance with the guidelines of the International Myeloma Working Group (IMWG) (the levels of 
SPEP, UPEP, FLC, and quantitative Ig should be confirmed as soon as they are known). 
11 PK sampling timepoints refer to Section 9.5.1. 
12 All serious adverse events that occur after patient signs the ICF (including prior to first dose) and the adverse events that occur after the first dose of (including serious 
adverse events). 
13 Telephone call (or visit) with patient to evaluate supportive care medications, concomitant medications and adverse events, and to adjust supportive care as appropriate. 
The telephone contact with the patient must take place on C1D3 (following administration of first dose of ATG-010 on C1D1). Survival follow up should be conducted 
via telephone call or in-person contact with the subject every 3 months until death or study discontinuation. MM disease status, survival, subsequent antineoplastic 
therapy, and drug-related SAE data will be collected at these phone calls/visits.  
14 The end of treatment (EoT) visit is considered to be ≤14 days after the last medication, and if it is more than 14 days after the last medication, the EoT visit will be 
performed within 1 week when the Investigator judges that the subject has permanently terminated the study drug. 
15After treatment discontinuation, if possible, for patients who are not progressing, SPEP with serum immunofixation, UPEP (24 h) with urine protein immunofixation, 
serum FLC, and quantitative Ig levels should be performed every 3 months for 1 year to assess durability of response. 
 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
16/77 
 
Table of Contents  
Medical Personnel/Emergency Contact Information ........................................................................ 2 
Signature Page of the Protocol ........................................................................................................ 3 
Study Site Principal Investigator Signature Page ............................................................................. 4 
Protocol Synopsis............................................................................................................................ 5 
Indication ................................................................................................................................. 5 
Objectives: ............................................................................................................................... 5 
Study Design ............................................................................................................................ 6 
Study Population ...................................................................................................................... 6 
Study Duration ......................................................................................................................... 9 
Study Drug, Dose and Administration: ..................................................................................... 9 
Concomitant medications ......................................................................................................... 9 
Study Endpoints ..................................................................................................................... 10 
Criteria for Treatment Discontinuation: .................................................................................. 10 
Statistical Summary................................................................................................................ 11 
Table of Contents  ........................................................................................................................ 16 
Listing of Tables ........................................................................................................................... 21 
List of Abbreviations ..................................................................................................................... 22 
1. 
Overview............................................................................................................................... 26 
2. 
Multiple Myeloma ................................................................................................................. 28 
3. 
Nuclear Export ...................................................................................................................... 29 
3.1. Inhibiting XPO1 in Human Cancer ................................................................................. 29 
4. 
ATG-010 (Selinexor) ............................................................................................................. 31 
4.1. Preclinical Data .............................................................................................................. 31 
4.1.1. ATG-010 Plus Dexamethasone Studies ................................................................ 32 
4.2. Clinical Experience ........................................................................................................ 32 
4.2.1. Efficacy Results of Study KCP-330-001............................................................... 32 
4.2.2. Efficacy Results of Study KCP-330-012 (STORM) .............................................. 33 
4.2.3. Clinical Safety Results ......................................................................................... 34 
4.3. Potential Risk ................................................................................................................. 34 
4.3.1. Reproductive Risks .............................................................................................. 35 
5. 
Rationale ............................................................................................................................... 36 
5.1. Rationale for ATG-010 Dose Regimen ............................................................................ 36 
6. 
Study Objectives and Endpoints ............................................................................................ 37 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
17/77 
 
6.1. Objectives: ..................................................................................................................... 37 
6.1.1. Primary Objective ................................................................................................ 37 
6.1.2. Secondary Objectives ........................................................................................... 37 
6.2. Study Endpoints ............................................................................................................. 37 
6.2.1. Primary Endpoint ................................................................................................. 37 
6.2.2. Secondary Endpoints ............................................................................................ 37 
7. 
Study Design ......................................................................................................................... 38 
7.1. Overview ........................................................................................................................ 38 
7.2. Independent Review Committee ..................................................................................... 38 
7.3. Study Stopping Rules ..................................................................................................... 38 
7.4. Study Endpoints ............................................................................................................. 39 
7.5. End of Study ................................................................................................................... 39 
8. 
Selection of Patients .............................................................................................................. 40 
8.1. Number of Patients ......................................................................................................... 40 
8.2. Inclusion Criteria ............................................................................................................ 40 
8.3. Exclusion Criteria ........................................................................................................... 41 
8.4. Screening Failures .......................................................................................................... 42 
8.5. Study Patient Number ..................................................................................................... 42 
9. 
Assessment Methods and Endpoints ...................................................................................... 43 
9.1. Standard Study Assessments ........................................................................................... 43 
9.1.1. Demographics ...................................................................................................... 43 
9.1.2. Medical History ................................................................................................... 43 
9.1.3. Concomitant Medications..................................................................................... 43 
9.1.4. Physical Examination ........................................................................................... 43 
9.1.5. ECOG Scoring ..................................................................................................... 44 
9.2. MM disease specific assessments.................................................................................... 44 
9.2.1. Bone Marrow Aspirate for MM Diagnosis and Classification and Efficacy Evaluation
 45 
9.2.2. Bone Marrow Aspirate for MRD Analysis ............................................................ 45 
9.2.3. Bone Marrow Biopsy for Efficacy Confirmation .................................................. 45 
9.3. Multiple Myeloma Response Criteria.............................................................................. 46 
9.4. Safety Evaluation ........................................................................................................... 46 
9.4.1. 12 Lead ECG ....................................................................................................... 46 
9.4.2. Clinical Laboratory Assessments .......................................................................... 47 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
18/77 
 
9.4.3. Pregnancy Test ..................................................................................................... 48 
9.5. Pharmacokinetic ............................................................................................................. 48 
9.5.1. PK Sampling Points ............................................................................................. 48 
9.5.2. Pharmacokinetic Endpoints .................................................................................. 48 
10. Study Discountinuation Criteria............................................................................................. 49 
10.1. Premature Termination of Study .................................................................................... 49 
10.2. Premature Termination of Study by Individual Patients ................................................. 49 
11. Treatment .............................................................................................................................. 50 
11.1. Dosage and Administration ............................................................................................. 50 
11.1.1. Dose Adjustment .................................................................................................. 50 
11.1.2. Label .................................................................................................................... 50 
11.1.3. TREATMENT INFORMATION .......................................................................... 50 
11.1.4. Dosage Adjustments in Patients with VGPR ......................................................... 50 
11.1.5. Guidelines for Dose Reduction due to Toxicity..................................................... 51 
11.2. Study Drug Storage ........................................................................................................ 54 
11.3. Study drug Accountability .............................................................................................. 54 
11.4. Concomitant therapies .................................................................................................... 55 
11.4.1. 5-HT3 Antagonists Required ................................................................................ 55 
11.4.2. Supportive Care ................................................................................................... 55 
11.4.3. Infection............................................................................................................... 55 
11.4.4. Concomitant Medications and Therapies .............................................................. 56 
11.4.5. Restricted Medications ......................................................................................... 56 
11.4.6. Prohibited Medicines ........................................................................................... 56 
11.4.7. Contraception Requirements ................................................................................ 57 
11.4.8. Radiation Therapy ................................................................................................ 58 
11.5. Treatment Compliance .................................................................................................... 58 
12. Adverse Event ....................................................................................................................... 59 
12.1. Serious Adverse Event .................................................................................................. 60 
12.1.1. Follow-up of AE and SAE .................................................................................... 61 
12.1.2. Post-study AE and SAE........................................................................................ 61 
12.1.3. Report of Serious Adverse Events ........................................................................ 61 
12.2. Overdosage ................................................................................................................... 62 
12.3. Pregnancy ..................................................................................................................... 62 
13. Statistical considerations ....................................................................................................... 63 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
19/77 
 
13.1. Overall Considerations .................................................................................................. 63 
13.1.1. Statistics and Analysis Plan .................................................................................. 63 
13.1.2. Sample Size Determination .................................................................................. 63 
13.1.3. Patient Disposition ............................................................................................... 63 
13.1.4. Blinding and Randomization ................................................................................ 63 
13.1.5. Dose Adjustment .................................................................................................. 64 
13.2. Analytical Dataset ......................................................................................................... 64 
13.2.1. Analysis Population ............................................................................................. 64 
13.3. Data Analysis and Presentation...................................................................................... 64 
13.3.1. Demographic Characteristics ................................................................................ 64 
13.3.2. Baseline Characteristics and Medical History ....................................................... 65 
13.3.3. Primary Endpoint ................................................................................................. 65 
13.3.4. Secondary Endpoints ............................................................................................ 65 
13.3.5. Pharmacokinetic................................................................................................... 66 
13.3.6. Safety Data .......................................................................................................... 66 
13.3.7. Missing Data Handling Procedures ...................................................................... 68 
13.4. Changes in Study Conduct or Planned Analyses ............................................................ 68 
14. Regulatory Considerations..................................................................................................... 69 
14.1. International Conference on Harmonization – Good Clinical Practices .......................... 69 
14.2. Investigator’s Responsibilities ....................................................................................... 69 
14.3. Subject Information and Informed Consent ................................................................... 69 
14.4. Confidential .................................................................................................................. 70 
14.5. Protocol Amendment ..................................................................................................... 70 
14.6. Institutional Review Board/Independent Ethics Committee Review and Approval ......... 70 
14.7. Continuously Providing Information to Institutional Review Board/Independent Ethics 
Committee ...................................................................................................................... 71 
14.8. End of Study ................................................................................................................. 71 
15. Data Processing and Records Keeping ................................................................................... 72 
15.1. Data/Documents ............................................................................................................ 72 
15.2. Data Management ......................................................................................................... 72 
15.3. Study-related Records Keeping ..................................................................................... 72 
15.4. Information Disclosure .................................................................................................. 73 
15.5. Reporting and Release of Study Documents .................................................................. 73 
16. Quality Control and Quality Assurance .................................................................................. 74 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
20/77 
 
16.1. Study Monitoring and Source Data Verification ............................................................. 74 
16.2. Auditing and Inspection ................................................................................................ 74 
17. References ............................................................................................................................. 75 
Appendix 1. Eastern Cooperative Oncology Group (ECOG) Performance Status Criteria.............. 79 
Appendix 2. International Staging System for MM........................................................................ 79 
Appendix 3. International Myeloma Working Group Response Criteria, Myeloma ........................ 80 
Appendix 4. ATG-010 (SELINEXOR) Preparation and Administration ......................................... 83 
Appendix 5. Products Containing Glutathione (GSH), S-adenosyl Methionine (SAM), or N-
acetylcysteine (NAC) (List of Representatives) ..................................................................... 84 
 
 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
21/77 
 
Listing of Tables 
Table 1:  Schedule of Assessments and Study Activities .............................................................. 12 
Table 1:  Schedule of Assessments and Study Activities (Continued) ........................................... 13 
Table 2:  Effects of XPO1 Inhibition on Oncogenic and Inflammatory Pathways ......................... 30 
Table 3:  Overall Response Rate Assessed by IRC per IMWG Criteria in Different Subgroups of 
KCP-330-012 Study (Part 2 of STORM) ....................................................................... 33 
Table 4:  Special Assessments of MM .......................................................................................... 44 
Table 5:  Pre-specified Dose/Schedule Modification for AEs Related to Study Drug .................... 51 
Table 6:  Guidelines for Supportive Care and Dose Modification ................................................. 51 
Table 7:  Classification of AEs Listed Per Causal Relationship ..................................................... 60 
Table 8:  Eastern Cooperative Oncology Group (ECOG) Performance Status Criteria .................. 79 
Table 9:  International Staging System for MM ............................................................................ 79 
Table 10: International Myeloma Working Group Response Criteria (Kumar 2016) ...................... 80 
Table 11: Products Containing Glutathione (GSH), S-adenosyl Methionine (SAM), or N-
acetylcysteine (NAC) (List of Representatives) ............................................................. 84 
 
 
 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
22/84 
 
 
List of Abbreviations 
Abbreviations 
Definitions 
5-HT3 
5 hydroxytryptamine 
ACS 
Acute cerebellar syndrome 
AE 
Adverse Event 
ALT 
Alanine aminotransferase (SGPT) 
AML 
Myeloid leukemia, acute 
ANC 
Absolute Neutrophil Count 
aPTT 
Activated partial prothrombin time 
ASCT 
Autologous stem cell transplantation 
AST 
Aspartate aminotransferase (SGOT) 
AUClast 
Area under the curve from the time of first measurement to the time of last measurement 
AUC0-∞ 
Area under the curve from time 0 to the last measurement 
AV 
Atrioventricular 
bid 
Twice daily 
BMSC 
Bone marrow stromal cells 
BP 
blood pressure 
BSA 
body surface area 
BSC 
Best support care 
BUN 
BUN 
℃ 
Degrees Celsius 
CBC 
Complete blood count 
CBR 
Clinical Benefit Rate 
CD 
Cluster of differentiation 
抗CD38 mAb 
Leukocyte-expressed monoclonal antibody against CD38 antigen 
CD-ROM 
Compact disc read-only memory 
CFR 
Code of Federal Regulations 
CHF 
Congestive cardiac failure 
CI 
confidence interval 
CLL 
Chronic lymphoid leukemia 
Cm 
Centimeter 
Cmax 
Maximum serum concentration 
CML 
Chronic myelogenous leukaemia 
CNS 
central nervous system 
CR 
complete response 
CRA 
Clinical Research Associate 
CRF 
Case Report Form 
CRM1 
Chromosomal region maintenance 1 
CSF 
CSF 
CTCAE 
Common Terminology Criteria for Adverse Events 
CTEP 
Cancer Therapy Evaluation Program 
cyclo 
amide 
DCR 
Disease Control Rate 
Dex 
Dexamethasone 
DLBCL 
Diffuse large B-cell lymphoma 
DLT 
Dose-limiting Toxicity 
DM 
Diabetes 
DNA 
deoxyribonucleic acid 
DOR 
Duration of response 
Dox 
Doxorubicin 
DSMC 
Data and Safety Monitoring Committee 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
23/84 
 
 
DT 
Dexamethasone + Thalidomide 
ECG 
electrocardiogram 
eCRF 
Electronic case report form 
eDC 
Electronic Data Capture 
ECOG 
Eastern Cooperative Oncology Group 
EDTA 
Ethylenediaminetetra acetic acid 
F% 
Oral bioavailability 
F 
Degree Fahrenheit 
FACT-G 
Functional Assessment of Cancer Therapy (General) 
FACT-MM 
Functional Assessment of Cancer Therapy-Multiple Myeloma 
FDA 
Food and Drug Administration 
FFPE 
Formalin-fixed Paraffin Embedded 
FISH 
Fluorescence in situ hybridization 
FLC 
Free light chain (κ/λ ratio) 
FLT3 
Fms-like tyrosine kinase 
GCP 
Good Clinical Practice 
G-CSF 
Granulocyte Colony-Stimulating Factor 
GGT 
Gamma-glutamyl transaminase 
GI 
gastrointestinal 
GM-CSF 
Granulocyte Macrophage Colony-Stimulating Factor 
GRP 
Growth regulator protein 
GSH 
Glutathione 
Hb 
Hemoglobin 
HBsAg 
Hepatitis B surface antigen 
HBV 
Hepatitis B virus 
hCG 
Human chorionic gonadotropin 
HCV 
Hepatitis C virus 
HIPAA 
Health Insurance Portability and Accountability Act 
HIV 
human immunodeficiency virus 
HPLC/MS-MS 
High performance liquid chromatography-tandem mass spectrometry 
hr 
Hours 
IC50 
Median inhibitory concentration (half maximal inhibitory concentration) 
ICF 
Informed Consent Form 
ICH 
International Council on Harmonisation 
IEC 
Independent Ethics Committee 
IFNα 
Interferon alpha 
IFNγ 
Interferon gamma 
IgA 
Immunoglobulin A 
IgVH 
Immunoglobulin heavy-chain gene variable region 
IL-1α 
Interleukin-1α 
IL-6 
Interleukin-6 
IL-8 
Interleukin-8 
IL-10 
Interleukin-10 
IMiD 
Immunomodulatory agent 
IMWG 
International Myeloma Working Group 
INR 
International Normalized Ratio 
IRC 
Independent Review Committee 
ISS 
International Staging System 
ITT 
Intention-to-treat 
IV 
Intravenous 
kg 
Kilogram 
KM 
Kaplan-Meier 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
24/84 
 
 
LAFB 
Left anterior bundle branch block 
LDH 
Lactate Dehydrogenase 
LMW 
low-molecular weight 
LOCSIII 
Lens Opacities Classification System 
m2 
Square meter 
MAb 
monoclonal antibody 
MCP1 
Monocyte chemotactic protein-1 
MedDRA 
Medical Dictionary for Regulatory Activities 
mg 
milligram 
MHRA 
Medicines and Healthcare Products Regulatory Agency 
MI 
Myocardial Infarction 
min 
Minutes 
miRNA 
microRNA 
mL 
Millilitre 
mITT 
Modified intent-to-treat 
MM 
Multiple Myeloma 
mmHg 
millimeters of mercury 
MTD 
maximum tolerated dose 
MR 
Minimal response 
mRNA 
messenger ribonucleic acid 
MUGA 
multigated acquisition 
5'NT 
5'-nucleotidase 
NAC 
N-acetylcysteine 
NCCN 
National Comprehensive Cancer Network 
NCI 
National Cancer Institute 
NES 
Nuclear export sequence 
NHL 
Non-Hodgkin’s lymphoma 
NK1R 
Neurokinin 1 receptor 
NPC 
Nuclear pore complex 
NPM1 
Nucleophosmin 
NYHA 
New York Heart Association 
OPG 
Osteoprotegerin 
ORR 
Overall response rate 
OS 
Overall survival 
PCR 
PCR 
PD 
Disease progression 
PDn 
Pharmacodynamics 
PE 
Physical examination 
PFS 
Progression Free Survival 
PI 
Proteasome inhibitor (in the context of drug therapy) 
PI 
Principal Investigator (in the clinical context) 
PK 
pharmacokinetic 
po 
Oral 
PP 
per-protocol 
PPI 
Proton pump inhibitors 
PR 
partial response 
prn 
On demand 
PT 
Prothrombin time 
qAM 
Every morning 
qd 
Once daily 
qhs 
At bedtime 
qid 
4 times daily 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
25/84 
 
 
QoL 
quality of life 
qRT-PCR 
Real-time quantitative polymerase chain reaction 
RBBB 
Right bundle branch block 
RBC 
Red blood cell 
RNA 
ribonucleic acid 
RP2D 
Recommended Phase 2 dose 
RPPA 
Reverse phase protein array 
RR 
Resistant/refractory 
RT 
Richter transformation 
SAE 
Serious Adverse Event 
SAM 
S-adenosyl methionine 
sCR 
Stringent complete response 
Sd 
ATG-010 80 mg plus Dexamethasone 20 mg (“low-dose” dexamethasone) 
SD 
stable disease 
SIADH 
Syndrome of inappropriate antidiuretic hormone secretion 
SINE 
Selective inhibitor of nuclear export 
SOC 
Standard of Care (in the context of treatment) 
SOC 
System Organ Class (in the context of adverse events) 
SOP 
Standard operating procedure 
SPEP 
Serum protein electrophoresis 
SR 
survival rate 
TEAE 
Treatment-emergent AEs 
TRAE 
Treatment-related adverse event 
tid 
3 times daily 
TK 
Toxicokinetics 
Tmax 
Time to maximum drug concentration 
TNFα 
Tumor necrosis factor α 
TOI 
Trial Outcome Index 
TSH 
Thyroid Stimulating Hormone 
TSP 
Tumor suppressor protein 
TTP 
Time to progression 
TUNEL 
Terminal deoxynucleotidyl transferase dUTP nick end labeling 
ULN 
Upper Limit of Normal 
UPEP 
Urine protein electrophoresis 
VEGFα 
Vascular endothelial growth factor α 
VGPR 
Very good partial response 
WBC 
white blood cell 
XPO1 
Exportin 1 
 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
26/84 
 
 
1. 
 Overview 
Multiple myeloma (MM) is the second most common hematological malignancy (following 
non-Hodgkin’s lymphoma), representing 1% of all cancers and 2% of all cancer deaths. Despite the 
significant increase in the efficacy of first-line drugs such as immunomodulatory agents and 
proteasome inhibitors, most patients will eventually relapse with their diseases and becomerefractory 
to the treatments, and their diseases are characterized by manifest resistance against all types of 
existing anti-MM therapies. In the United States alone, it is expected that about over 30,000 new 
cases will be diagnosed and there will be approximately 12,600 deaths due to MM in 2016 (ACS 
2016), which indicates an unmet need for the new therapies of refractory MM that can improve the 
overall survival rate. 
ATG-010 (Selinexor) is a selective inhibitor of nuclear export (SINE) compound that can bind and 
inactive Exportin 1 (XPO1), and thereby compeling the nuclear tto retain key tumor suppressor 
protein (TSP). The level of XPO1 protein is significantly elevated in MM, which leads to nuclear 
exclusioin of TSP, the glucocorticoid receptors (GR), and enhanced translation of certain oncogene 
mRNAs (Tai 2014). High-level TSP is retained in the nucleus for a short time by blocking XPO1, 
thus activating its cell cycle checkpoints and genomic survey function. This results in the death of 
almost all types of malignant tumor cells, whilst normal cells experience transient cell cycle arrest 
and recover after the export blockage is released. XPO1 also exports GR and thereby causing a decline 
in its transcriptional activity. In the presence of glucocorticoids in the body, XPO1 blocking may lead 
to nuclear accumulation and activation of GR. In addition, inhibition of XPO1 induces nuclear to trap 
cap-binding protein (eIF4E)-dependent oncogenic mRNAs, preventing these oncogenes from being 
translated into proteins in the cytoplasm. In this way, SINE causes a reduction in key oncoproteins 
such as c-Myc, cyclin D, hDM2, and others. Moreover, inhibition of XPO1 protein reactivates 
multiple TSP pathways and glucocorticoid signaling together with reduced translation of key 
oncoproteins. This makes SINE a noval treatment for tumors including those with a variety of 
genomic changes and drug resistance mechanisms. 
Based on the data of the Phase 2b clinical trial (STORM) conducted in patients with MM refractory 
to five agents (lenalidomide, pomalidomide, bortezomib, carfilzomib, and an anti-CD38 monoclonal 
antibody), on July 3, 2019, FDA approved selinexor (Xpovio@) in combination with dexamethasone 
for the treatment of adult patients with relapsed or refractory MM who have received at least four 
prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two 
immunomodulatory agents, and an anti-CD38 monoclonal antibody. 
The Phase 1 clinical trials with oral ATG-010 monotherapy have been conducted in advanced 
hematologic malignancies including MM, acute myeloid leukemia (AML), non-Hodgkin’s 
lymphoma (NHL), and chronic lymphocytic leukemia (CLL) (KCP-330-001)], in solid tumors 
(KCP-330-002), and in soft-tissue and bone sarcoma (KCP-330-003). So far, these studies have 
demonstrated an extensive antitumor activity of ATG-010. In addition, Phase 2 studies are now 
ongoing in patients with MM, AML, diffuse large B-cell lymphoma (DLBCL), Richter's syndrome, 
glioblastoma, gynecological malignancy, and dedifferentiated liposarcoma (DDLS). As of March 
2019, more than 3,000 patients with advanced hematologic diseases and solid tumors worldwide have 
received ATG-010 treatment in clinical trials. 
To date, the most common adverse events (AEs) of ATG-010 found in clinical studies are 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
27/84 
 
 
thrombocytopenia, anorexia, fatigue, nausea, and vomiting. These adverse events can be resolved or 
eliminated by standard supportive care. Besides, the prevlence and intensity of these AEs are usually 
decreased after 4 to 8 weeks of treatment. ATG-010 treatment is not associated with clinically 
significant major organ toxicities. Moreover, no clinically relevant cumulative toxicity has been 
observed in patients with longterm ATG-010 treatment, this includes 28 patients who have received 
ATG-010 monotherapy for more than 1 year and 6 patients who have received ATG-010 
monotherapy for more than 2 years. For more information, please refer to the current Investigator’s 
Brochure (IB). 
In a Phase 1 dose-escalation clinical study, ATG-010 has shown a durable, single-agent, anticancer 
activity in patients with a variety of RR hematological and solid tumor malignancies (including MM), 
at doses ≥ 6 mg/m2 body surface area (BSA). 
Since ATG-010 has been demonstrated to activate glucocorticoid signaling via its receptor, patients 
received low-dose dexamethasone (20 mg) therapy in the previous Phase 2b clinical study as to 
improve the tolerability of ATG-010 and increase efficacy benefits. In previous studies, 
dexamethasone has also been demonstrated to be an effective prophylactic treatment the 
aforementioned common adverse events of ATG-010. Therapy naive MM is particularly sensitive to 
glucocorticoids, but the clinical benefits of glucocorticoids decrease with the prolongedtreatment 
duration involving multi-drug combination therapies. ATG-010 in combination with dexamethasone 
can re-activate glucocorticoid receptor (GCR) signaling to produce a synergistic effect on the clinical 
treatment of MM. The current study will evaluate the efficacy and safety of ATG-010 plus 
dexamethasone in the treatment of Chinese patients with relapsed/refractory MM who have 
previously received regimens of lenalidomide (immunomodulatory agent) and bortezomib 
(proteasome inhibitor). 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
28/84 
 
 
2. 
Multiple Myeloma 
Multiple myeloma (MM) is a hematologic malignancy that is characterized by accumulation of 
monoclonal plasma cells in bone marrow, presence of monoclonal immunoglobulins or M-proteins 
in serum or urine, bone disease, impaired renal function, and immunodeficiency. MM is more 
common in elderly patients (the median age at the diagnosis of the disease is 65-70 years; only 2% 
of the patients are under the age of 40 years) (Raab 2009). 
MM is the second most common hematological malignancy (following non-Hodgkin’s lymphoma), 
representing 1% of all cancers and 2% of all cancer deaths. Study suggests that, the median survival 
after diagnosis is 5.2 years with current standard of care (Kumar 2014). 
Although the pathogenesis of MM is unknown, studies have found that, a variety of mutated genes, 
including NRAS, KRAS, TP53, and BRAF mutations, occur frequently in MM patients; These 
mutations are universally acknowledged as the causal drivers for other cancers (Lohr 2014). In 
addition, some risk factors may make patients more susceptible to this disease. MM is more common 
in the elderly ≥ 65 years, in males, and in those with a family history of MM. 50% of MM patients 
have the following gene and chromosome mutations, including mutation of immunoglobulin heavy 
chain gene locus on chromosome 14 q32, partial or complete loss of chromosome 13, and partial loss 
of chromosome 17 (Raab 2009; Kyle 2004). 
The related diagnosis of MM is based on the disease’s key characteristics, space-occupying lesion(s) 
in the bone marrow cavity, bone lesions, and production of paraproteins (Raab 2009; IMWG 2003). 
MM is staged by the β2-microglobulin level, which is directly related to the renal function, tumor 
mass, and albumin level (Greipp 2005). See Appendix 2 for the summary of staging. 
In the past 20 years, due to the use of high-dose chemotherapy (i.e., alkylating agent) and autologous 
stem cell transplantation plus the developement and application of some new drugs including 
immunomodulatory agents (e.g., thalidomide, lenalidomide, and pomalidomide) and proteasome 
inhibitors (bortezomib and carfilzomib), the treatment of MM has been greatly improved. However, 
despite the increased efficacy of these drugs, majority of the patients develop highly drug resistance 
MM gradually, then they relapse and become refractory to treatments and eventually die from the 
disease. The epidemiological study showed that 12,500+ people in the United States died from MM 
in 2016 (ACS 2016), which indicates great unmet medical needs and the necessity for developing 
anti-MM agents with noval mechanisms. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
29/84 
 
 
3. 
Nuclear Export 
3.1. 
Inhibiting XPO1 in Human Cancer 
Many important tumor suppressor proteins (TSPs), including but not limited to TP53, FOXO3a, IκB, 
BRCA1, APC, PP2A, and Rb, have been identified in the pathogenesis of cancer. TSP mediates tumor 
suppressor pathways through a variety of functions, including identification of cell damage, cell cycle 
arrest until repair is made, and induction of irreparable apoptosis (Brown 2011). Similarly, for binding 
with glucocorticoids and nuclear localization, GCR is essential for its signaling. 
The tumor suppression and anticancer activity of these TSPs and GCRs demands their presence in 
the nucleus. On the contrary, their ability to regulate the cellular process can be inactivated when 
exported to the cytoplasm by the nuclear export protein (XPO1), (Xu 2010), through which cancer 
cells can successfully escape from normal DNA damage control and antitumor treatment. For most 
TSPs and GCRs, XPO1 is the only known nuclear export protein. It should be noted that, XPO1 has 
been identified as a selective survival gene in MM by unbiased high-throughput short interfering 
RNAs (siRNA) screening (Tiedemann 2012) and is often overexpressed in MM (Tai 2014). 
The blocking of XPO1 causes transient nuclear retention of TSP, GCR and other growth regulatory 
factors and thereby reconstructing their tumor suppressor effect and growth regulatory effects on 
cancer cells, which allows potential reversal of the mechanism that causes resistance to chemotherapy 
(this may make sense for combination therapies in the future) (Lain 1999). 
Some growth-promoting (including oncogenes) messenger RNAs (mRNAs) are particularly exported 
from the nucleus through a “cap-binding complex” to the cytoplasm, where they are further translated 
into proteins (Culjkovic 2013; Koehler 2007). Several key MM genes including c-Myc, cyclin D1, 
and hDM2, etc. utilize this complex by binding to the protein eIF4E, and thereby exit the nucleus and 
then are effectively translated into proteins. Only XPO1 can make the cap-binding complex protein 
eIF4E exported out of the nucleus to the cytoplasm. As these proteins have an extremely short half-life, 
constant translation is required for maintaining their cellular levels. Inhibition on XPO1-mediated 
nuclear export can lead to a decline in the translation of these growth-promoting proteins, thereby 
significantly reducing their levels. 
In normal cells, XPO1 inhibition can lead to transient cell cycle arrest without resulting in any 
cytotoxicity, and normal cell cycles can be restored after the inhibition is removed (Lain 1999; van 
der Watt 2009; Gray 2007). 
Inthe early clinical trials, subjects experienced significant of weight loss, diarrhea, and marked fatigue 
and asthenia due to off-target effects of the drug; as a result, several attempts to develop such class 
of anticancer drugs all failed (Mutka 2009; Newlands 1996; Roberts 1986). 
It is now fully recognized that, forced nuclear retention of TSP can block a great number of 
tumorigenic growth stimulation (and inflammation) pathways that maintain the phenotype of 
malignant tumors. Likewise, in the presence of glucocorticoids, nuclear retention of GR can restore 
its activity. Eventually, inhibition of eIF4E/XPO1-mediated mRNA export of oncoprotein can cause 
a decrease in its level. Since the restoration of TSP ± GR activity and tumorigenic signal reduction 
are essentially associated with any cancer, the inhibition of XPO1 has an anti-tumor activity against 
MM and many other malignancies (Table 2). 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
30/84 
 
 
 
Table 2:  Effects of XPO1 Inhibition on Oncogenic and Inflammatory Pathways 
Pathway Affected 
Effect of XPO1 Inhibition 
References 
XPO1 overexpression 
XPO1 reduction 
Walker 2013 
Glucocorticoid receptor (GR) In 
activation (nuclear export) 
Nuclear GR retention (in the presence of 
glucocorticoids) and re-activation 
Chen 2014 
p53 mutation 
p73 activation, p21 activation 
Ranganathan 2012 
hDM2 (MDM2) activation 
Nuclear p53 retention and activation, hDM2 
protein reduction 
Kojima 2013 
c-Myc amplification 
MYC protein reduction 
Schmidt 2013 
Cyclin D1 overexpression 
Cyclin D1 reduction 
Gao 2014 
NPM1 mutation 
Nuclear restoration of NPM1 
Falini 2007 
CEBPA down-regulation 
Nuclear retention and activation 
Ranganathan 2012 
CDKN2A reduction 
P53/p73 stabilization 
Azmi 2013 
Rb reduction 
Rb low phosphorylation, p14/p16 elevation 
Fragomeni 2013 
FLT3 activation 
FLT3 reduction 
Ranganathan 2012 
c-KIT activation 
c-KIT reduction 
Ranganathan 2012 
NF-B activation 
Nuclear retention and activation of IκB 
Lapalombella 2012 
PIK3 or AKT activation 
FOXO1, -3, -4 activation 
Lapalombella 2012 
Survivin-cytoplasm 
Nuclear retention of survivin 
Altura 2003 
Bcr-Abl activation 
PP2A activation 
Walker 2013 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
31/84 
 
 
4. 
ATG-010 (Selinexor) 
ATG-010 is an innovative, orally bioavailable, slowly reversible, potent selective inhibitor of nuclear 
export (SINE) compound that specifically blocks exportin 1 (XPO1). XPO1 is responsible for the 
unidirectional export of approximately 220 different cargo proteins out of the nucleus to the 
cytoplasm (Xu et al., 2010). The anti-tumor activity of SINE compound is mediated by a minimum 
of 3 distinct pathways, involving tumor suppressor proteins (TSP), oncoproteins, and glucocorticoid 
receptors (GCR). 
First, SINE compounds induce the nuclear localization and functional activation of a variety of TSPs, 
thereby leading to rapid apoptosis of multiple myeloma (MM) (ai et al., 2014) and other malignant 
tumor cells. By forcing the nuclear localization and activation of TSP, all types of cells exposed to 
SINE compounds experience G1±G2 cell cycle arrest, and then ‘genomic fidelity’ check. 
Genomedamaged cells (i.e., malignant tumor cells) are induced to die both in vitro and in vivo. 
Normal cells with intact genome stay in reversible, transient cell cycle arrest until the blocking of 
XPO1 is relieved. The second antitumor effect of SINE compounds is mediated by the mRNA 
cap-binding protein eIF4E, which is also a cargo protein carried by XPO1. Among other functions, 
eIF4E is responsible for effective nuclear export and delivering several kinds of growth promoting 
(oncoprotein) mRNAs to the cytoplasmic ribosome for translation. By forcing the nuclear retention 
of eIF43 bonded to XPO1, SINE compounds reduce the synthesis of oncoprotein mRNAs by 
cytoplasmic ribosome including c-Myc, hDM2, cyclin D1, and Bcl-XL. Finally, in the presence of 
glucocorticoids, SINE compounds also enable restoration of anti-myeloma glucocorticoid receptor 
(GR) signaling; meanwhile, ATG-010 and other SINE compounds will not enhance the 
hyperglycemic effects of glucocorticoids. Therefore, by inhibiting the key nuclear/cytoplasmic 
control protein XPO1, the SINE compounds exhibit an extensive and intensive anticancer activity. 
4.1. 
Preclinical Data 
This section briefly summarizes previous preclinical data. For more information, please refer to the 
Investigator’s Brochure. 
According to in vitro experiment of continued (approximately 72 hours) exposure to ATG-010, 
ATG-010 promoted cancer cell apoptosis in a wide range of tumor-derived cell lines and patient 
samples in culture (including multi-drug resistant cancer). In addition, in the absence or presence of 
bone marrow stromal cells (BMSCs), ATG-010 was cytotoxic to both MM and CLL cells. 
Animal model pharmacokinetic (PK) studies were conducted in mice, rats and monkeys. The results 
showed that, the exposure of ATG-010 was proportional to the dose and there was no accumulation. 
For more information, please refer to the latest Investigator’s Brochure. 
The in vivo effects of SINE compounds on MM have be evaluated in several studies. In MM1.S 
xenograft tumors, tumor volume significantly decreased (40%) after treatment with the SINE 
compound KPT-276, whereas tumor volume increased by 36% in the placebo-treated cohort (Schmidt 
2013). KPT-276 was also active in the Vk*MYC mouse model of MM, which has a positive 
predictive value of 67% for the activity of single-agent compounds in clinical trials (Schmidt 2013; 
Chesi 2012). 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
32/84 
 
 
4.1.1. 
ATG-010 Plus Dexamethasone Studies 
In vitro studies, compared to either drug alone, ATG-010 and dexamethasonein combination have 
synergistic activity on reducing the viability of MM1.S human MM cells (Chen 2014). In the presence 
of glucocorticoids, enhanced GR nuclear localization with activated GCR mediated transcription is 
at least partly related to the synergistic cytotoxicity of this combination therapy (Gao 2014). 
The enhanced activity of ATG-010 plus dexamethasone was also observed in two human MM 
xenograft models. Compared to ATG-010 alone, the addition of dexamethasone to ATG-010 
enhanced the activity (86%). 
Given all that above, in MM cytotoxicity assays, ATG-010 plus dexamethasone showed synergistic 
effect both in vitro and in vivo by enhancing GCR nuclear localization and amplifying GCR 
transcriptional activity. In summary, these studies proved that, SINE compounds are active anti-MM 
compounds that reduce cell viability, cause increased apoptosis and cell cycle arrest in vitro, and 
potently inhibit the growth of MM tumor in vivo, and such effects can be enhanced by their 
combination with dexamethasone. 
4.2. 
Clinical Experience 
A total of 686 MM patients received selinexor treatment in four clinical studies (KCP-330-001, -
012, -017, and -023). Both selinexor alone and its combination with dexamethasone were evaluated 
(studies KCP-330-001 and KCP-330-012). Study KCP-330-017 is evaluating the combination of 
selinexor with various therapeutic MM drugs, including pomalidomide, lenalidomide, carfilzomib, 
bortezomib, and daratumumab. The primary objective is to evaluate the preliminary efficacy and 
safety, and determine the recommended phase 2 dose (RP2D). Study KCP-330-023 is evaluating 
and comparing the safety and efficacy of selinexor+bortezomib+low-dose dexamethasone (SVd) vs. 
bortezomib+low-dose dexamethasone (Vd). The preliminary efficacy and safety data of studies 
KCP-330-001 and KCP-330-012 are summarized below (both studies KCP-330-017 and -023 are 
still ongoing). 
4.2.1. 
Efficacy Results of Study KCP-330-001 
Study KCP-330-001 was a Phase I, open-label, parallel-group study, with dose escalation and dose 
expansion phase, to determine the MTD, to evalute preliminary safety and efficacy of different 
selinexor dose schedules (3-80 mg/m2, 1 to 3 times per week). 
The results showed that, for all patients with MM (regardless of selinexor dose; n = 81), the overall 
response rate (ORR) was 8.6% (95%CI: 4%, 17%), including 1 patient with stringent complete 
response (sCR; 1.2%) and 6 patients with partial response (PR; 7.4%). The best response in another 
13 patients (16%) was minimal response (MR), and the clinical benefit rate (CBR) was up to 25%. 
29 patients (35.8%) had stable disease (SD), 20 (24.7%) patients had progressive disease (PD), and 1 
(1.2%) patient had clinical progression. 
Among the 81 selinexor-treated MM patients, 25 received selinexor (45 or 60 mg/m2, BIW) 
+dexamethasone (20 mg BIW). Within these 25 patients, the ORR was 24.0% (95%CI: 9%, 45%) 
and CBR was 32.0%, including 1 case of sCR, 5 PRs, and 2 MRs. Eight patients (32.0%) had SD, 
and 5 (20.0%) patients experienced PD. All responses ≥ PR occurred at the dose level of 45 mg/m2 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
33/84 
 
 
selinexor. 
Dose of 60 mg/m2 was poorly tolerated and made the duration of study treatment (median, 15.0 days) 
shorter than that of 45 mg/m2 (median, 110.5 days). In the 45 mg/m2 selinexor+20 mg dexamethasone 
group, the median time to disease relapse or progression was 180 days. Therefore, the RP2D of 
selinexor in MM was 45 mg/m2 (about 80 mg) +20 mg dexamethasone BIW. 
4.2.2. 
Efficacy Results of Study KCP-330-012 (STORM) 
STORM was a Phase 2b, open-label, single-arm study of selinexor+low-dose dexamethasone (Sd) 
in patients with relapsed/refractory MM. In Part 1, patients must have been previously treated with 
lenalidomide, pomalidomide bortezomib, and carfilzomib; and were refractory to a PI, an 
immunomodulatory agent (IMiD), and glucocorticoids, and a subset of the patients also were 
refractory to the “quad” agents (quad-refractory) as well as to an anti-CD38 antibody (i.e. 
penta-refractory). Patients orally took 6 or 8 doses of selinexor 80 mg (BIW) and dexamethasone 
20 mg BIW in each 28-day cycle. The primary objective was to determine the ORR per 
International Myeloma Working Group criteria and DOR, both of which was assessed by an 
Independent Review Committee (IRC). 
In Part 2 of the STORM study, a total of 123 patients with RRMM received selinexor 80 mg plus 
dexamethasone 20 mg. In the modified intent-to-treat (mITT) efficacy population, 122 patients had 
an ORR of 26.2%, including 2 cases of sCRs (both assessed as MRD negative), 6 VGPRs, and 24 
PRs, as assessed by the IRC per IMWG criteria. The median time to initial response was 4 weeks 
(range: 1 to 10 weeks). The median OS was 8.6 months, 15.6 months for patients with ≥ PR or ≥ 
MR (two groups), and 1.7 months for those with PD (or NE). The PFS and OS were 4.7 and 9.3 
months, respectively. Of the 32.1% (25/78 cases) patients who achieved a response ≥ MR, the 
median OS was 11.4 months, compared to 5.8 months of those achieving SD, PD or NE. 
Table 3:  Overall Response Rate Assessed by IRC per IMWG Criteria in Different Subgroups 
of KCP-330-012 Study (Part 2 of STORM) 
Subgroup Population (n) 
Overall response rate 
n (%) 
95%CI 
Clinical Benefit Rate 
n (%) 
95%CI 
Prior anti-MM treatment 
Penta (BCLPD) refractory (n = 83) 
21 (25.3) 
31 (37.3) 
16.4, 36.0 
27.0, 48.7 
Refractory to CLPD (n = 101) 
26 (25.7) 
37 (36.6) 
17.6, 35.4 
27.3, 46.8 
Refractory to BCPD (n = 94) 
25 (26.6) 
18.0, 36.7 
36 (38.3) 
28.5, 48.9 
Refractory to CPD (n = 117) 
31 (26.5) 
45 (38.5) 
18.8, 35.5 
29.6, 47.9 
Other subgroup factors 
R-ISS stage I (n = 20) 
7 (35.0) 
10 (50.0) 
(15.4, 59.2) 
(27.2, 72.8) 
R-ISS stage II (n = 78) 
21 (26.9) 
32 (41.0) 
(17.5, 38.2) 
(30.0, 52.7) 
Prior anti-MM treatment 
R-ISS stage III (n = 23) 
4 (17.4) 
(5.0, 38.8) 
6 (26.1) 
(10.2, 48.4) 
FLC MM (n = 35) 
15 (42.9) 
19 (54.3) 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
34/84 
 
 
26.3, 60.6 
36.6, 71.2 
Non-FLC MM (n = 87) 
17 (19.5) 
11.8, 29.4 
29 (33.3) 
23.6, 44.3 
High-risk MM (n = 65) 
12 (18.5) 
9.9, 30.0 
24 (36.9) 
25.3, 49.8 
Impaired renal function 
CrCL <40 (n = 14) 
35.7 
NA 
CrCL 40 to <60 (n = 25) 
16.0 
NA 
CrCL ≥ 60 (n = 82) 
28.0 
NA 
Age 
≤60 years (n = 46) 
21.7 
NA 
>60 to 70 years (n = 49) 
28.6 
NA 
≥70 years (n = 27) 
29.6 
NA 
Prior anti-MM treatment: B = bortezomib; C = carfilzomib; L = lenalidomide; P = pomalidomide; D = daratumumab; 
CrCL = creatinine clearance; FLC = free light chain; NA = not applicable; R-ISS = Revised International Staging 
System 
4.2.3. 
Clinical Safety Results 
The most common TEAEs in the study were low-grade and reversible events and/or responded to the 
supportive care and dose modification. The most common TEAEs (≥35%) included nausea (65.1%, 
1352/2076 cases), fatigue (57.9%, 1203/2076 cases), thrombocytopenia (52.1%, 1082/2076 cases), 
anorexia (MedDRA “decreased appetite”) (51.0%, 1058/2076 cases), anemia (42.3%, 879/2076 
cases), vomiting (38.2%, 794/2076 cases), and diarrhea (36.0%, 747/2076 cases). 
4.3. 
Potential Risk 
On July 3, 2019, FDA granted accelerated approval to selinexor. Post-marketing experience will be 
provided in the periodic adverse drug reaction report. FDA approved selinexor in combination with 
dexamethasone for adult patients with RRMM who have received at least 4 lines of prior therapies 
and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory 
agents, and an anti-CD38 monoclonal antibody. 
This study will continue to evaluate the efficacy and safety of selinexor plus dexamethasone in 
Chinese patients with RRMM. Measures will be taken to guarantee the safety of patients participating 
in this trial, including formulating strict inclusion and exclusion criteria and closely monitoring 
subjects’ AEs. 
If a patient experiences an AE during the course of the clinical trial, the Investigator may adjust the 
study treatment according to the protocol. During the trial period, and within 30 days after the last 
dose of study treatment or prior to the initiation of another anti-cancer therapy, all AEs and serious 
adverse events (SAEs) will be recorded, whichever comes first. 
The most common AEs possibly related to ATG-010 are nausea, fatigue, thrombocytopenia, anorexia, 
anemia, vomiting, and diarrhea. In fact, all these side effects can be effectively managed with the 
modified dose of the study drug and/or the supportive care initiated prior to the first dose. Overall, 
the most common laboratory abnormalities includ thrombocytopenia, hyponatremia, and decreased 
erythrocytes. The majority of these AEs were mild or moderate in severity. For more information, 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
35/84 
 
 
please refer to the Investigator’s Brochure. 
Based on 3 reports, acute cerebellar syndrome (ACS) is assessed as a potential risk of selinexor. One 
adult patient who had previously received multiple therapies, had recurrent pancreatic cancer, and 
had baseline magnetic resonance imaging (MRI) evidence of cerebellar abnormality, experienced 
ACS. This patent received selinexor 145 mg, twice weekly (i.e., an extremely high dose that is no 
longer used). The other 2 cases of ACS occurred in pediatric patients with refractory AML. These 
patients also had baseline cerebellar abnormality and received selinexor treatment at extremely high 
doses (these doses are no longer recommended). Since these cases were reported in 2015, no new 
reports were found, and further studies on higher doses have been discontinued. In addition, using 
“cerebellar syndrome”, to search the newly obtained safety data in the studies sponsored by 
Karyopharm Therapeutics Inc., no new ACS cases were found. 
4.3.1. 
Reproductive Risks  
Macroscopic and microscopic changes of reproductive organs were observed in the toxicology studies 
of ATG-010 in rats and monkeys, and the majority of these changes recovered or partially recovered 
during the recovery period. The long-term effects of these changes on the reproductive capacity are 
unknown. In addition, secondary developmental effects due to decreased maternal body weight were 
observed in a rat embryo-fetal development study. For more information, please refer to the 
Investigator’s Brochure. Since it is unknown whether ATG-010 causes any reproductive toxicity in 
humansall patients must agree to take effective contraceptive measures during the study period and 
until 3 months after the end of study treatment. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
36/84 
 
 
5. 
Rationale 
MM is the second most common hematological malignancy. The median survival after diagnosis with 
conventional therapy is 5.2 years (Kumar 2014). Although MM is highly treatable, but it cannot be 
cured with existing therapies. Common therapies include glucocorticoids, chemotherapy, proteasome 
inhibitors, immunomodulatory agents, stem cell transplant, and radiotherapy. 
In preclinical studies, the anti-MM activity of ATG-010 has been demonstrated both in vitro and in 
vivo. The clinical outcomes of MM patients in studies KCP-330-001 and -012 are summarized in 
Section 4.2. 
In the Phase 2b trial (KCP-330-012) mentioned above, the 123 RRMM patients who received 
selinexor 80 mg plus dexamethasone 20 mg in Part 2 had an ORR of 26.2%, including 2 cases of 
sCRs (both assessed as MRD negative), 6 cases of VGPRs, and 24 cases of PRs. Relevant results 
have showed that the efficacy of ATG-010 combined with low-dose dexamethasone is encouraging 
in patients with RRMM who have previously received multi-line therapies and have limited treatment 
options. Based on the promising efficacy data observed from the study in the Western population of 
RRMM, the current study is planned to extended ATG-010 combined with low-dose dexamethasone 
to the treatment of RRMM patients in China, in order to validate the clinical efficacy and safety of 
ATG-010 in Chinese RRMM patients. 
The design of this study protocol is based on the initial treatment option for RRMM (i.e., lenalidomide 
and bortezomib), aiming to evaluate if ATG-010 provides such MM patients (i.e., second-line 
refractory MM patients) with a new effective treatment option. 
5.1. 
Rationale for ATG-010 Dose Regimen 
As of March 2019, more than 3000 patients with advanced cancer have received ATG-010 treatment 
in multiple clinical studies. In the previous clinical trial (KCP-330-001) and STORM study 
(KCP-330-012), patients who received ATG-010 45 mg/m2 (about 80 mg) plus dexamethasone 20 mg 
(both twice weekly) treatment achieved persistent response without any clinically significant 
cumulative toxicity (see Section 4.2). The recommended initial dose of selinexor approved by FDA 
is 80 mg in combination with dexamethasone taken orally on Days 1 and 3 of each week. This study 
plans to reducing dose according to the package inserts approved by FDA. 
Patients in this study will receive ATG-010 80 mg (45 mg/m2 BSA) plus dexamethasone 20 mg dosed 
both twice weekly in 4-week cycles. For patients who are partially intolerant to glucocorticoids 
(determined by the Investigator), the minimum dose of dexamethasone allowed is 10 mg. If the patient 
still fails to tolerate this dose, drug discontinuation or further dose reduction may be allowed after the 
Investigator has a discussion with the Sponsor’s Medical Monitor based on the specific situation. 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
37/84 
 
 
6. 
Study Objectives and Endpoints 
6.1. 
Objectives: 
6.1.1. 
Primary Objective 
To evaluate the overall response rate (ORR) for treatment with ATG-010 plus low‑dose 
dexamethasone in patients with relapsed/refractory MM previously treated with lenalidomide and 
bortezomib regimens. 
6.1.2. 
Secondary Objectives 
To evaluate the followingendpoints of ATG-010 in the study: 
a. Efficacy 
 
Survival rate (SR) at 6 months, 9 months, and 12 months 
 
Time to Progression (TTP) 
 
Progression Free Survival (PFS) 
 
Duration of response (DOR) 
 
Clinical Benefit Rate (CBR) 
 
Disease Control Rate (DCR) 
 
Overall Survival (OS) 
 
Minimal Residual Disease (MRD) 
 
The effect of risk factor stratification on clinical efficacy 
b. Safety and tolerability  
c. Pharmacokinetics (PK) parameters 
6.2. 
Study Endpoints 
6.2.1. 
Primary Endpoint 
ORR: Proportion of patients who achieve sCR, CR, VGPR, or PR  
6.2.2. 
Secondary Endpoints 
a. Efficacy: 
 
SR at 6 months, 9 months, and 12 months 
 
TTP: Duration from start of study treatment to time of disease progression 
 
PFS: Duration from start of study treatment to PD or death (regardless of cause), whichever 
comes first 
 
DOR: Duration from the first observation of at least PR to time of disease progression, or 
deaths due to disease progression, whichever occurs first. 
 
CBR: Proportion of patients who achieve sCR, CR, VGPR, PR, or minimal response (MR) 
 
DCR: Proportion of patients who achieve sCR, CR, VGPR, PR, MR, or stable disease (SD; 
for a minimum of 12 weeks) 
 
OS (Kaplan-Meier estimates) 
 
MRD in patients who achieve CR and sCR 
 
The effect of risk factor stratification based on fluorescence in situ hybridization (FISH) on 
clinical efficacy, including del 13, del 17p13, t (4;14), t (14;16), 1q21 amplification 
b. Safety and tolerability  
c. PK: including but not limited to ATG-010 Cmax and tmax 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
38/84 
 
 
7. 
Study Design 
7.1. 
Overview 
This is a Phase 2, single-arm, open-label, multi-center study of Sd (ATG-010 80 mg plus 
dexamethasone 20 mg) in patients with refractory MM who have previously received regimens with 
immunomodulatory agent and protease inhibitor (i.e., patients with relapsed/refractory MM who have 
previously received glucocorticoids, lenalidomide, and bortezomib) (note: “refractory” refers to a 
treatment response rate ≤25%, disease progression during the treatment described above, or disease 
progression within 60 days following the completion of treatment). This study plans to enroll 
approximately 82 patients to evaluate the efficacy, safety, and tolerability of Sd, and evaluate the 
pharmacokinetics (PK) of ATG-010 in 15 patients of enrolled. 
Patients will receive Sd treatment at dose of ATG-010 (80 mg) plus dexamethasone (20 mg) 
simultaneously twice weekly. The drugs should be taken twice each week at a fixed time (whenever 
possible), and the doses should be approximately 48 hours apart (e.g., Monday and Wednesday or 
Tuesday and Thursday, etc.). Each treatment cycle will last 4 weeks. Patients will receive the 
treatment until disease progression, death, toxicity that cannot be managed by the standard of care, 
or withdrawal of consent, whichever comes first. 
Patients will also receive blood product transfusions, antimicrobial agents, and growth factors 
including granulocyte colony-stimulating factors (for neutropenia), erythropoietins (for anemia), 
and/or platelet-stimulating factors (for thrombocytopenia), as best supportive care. 
Patients may decide to discontinue study treatment for any reason. Patients who elect to discontinue 
study treatment should be encouraged to stay in the study, so that follow-up information on disease 
progression, other antitumor therapy, symptoms, and survival status can be obtained. Patients can 
also decide to withdraw consent and decline further participation in the trial at any time. 
The Investigator must determine patient’s main reason for discontinuing study treatment and record 
this information in the electronic Case Report Form (eCRF). Patients who discontinue the study 
treatment prematurely will not be eligible for re-initiating the study treatment in this study protocol 
at a later date. 
7.2. 
Independent Review Committee 
The Independent Review Committee (IRC) will review the disease assessment data and 
independently assess the disease response. Disease response assessed by IRC is the basis for the 
evaluation of primary endpoint. 
The IRC membership, functions, and procedures (including resolving the disagreements with the 
Investigators regarding disease assessment) will be stipulated in the IRC Charter. 
7.3. 
Study Stopping Rules 
Under the prescribed conditions in Section 10, the entire study or treatment of individual patients may 
be stopped. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
39/84 
 
 
7.4. 
Study Endpoints 
See Section 6 for the study objectives and endpoints. 
7.5. 
End of Study 
The end of study (EoS) occurs when all patients have completed 12 months of study visit/follow-up 
since the initiation of the study drug, or when the last patient has expired, has been lost to follow-up, 
or has withdrawn consent, whichever occurs first. After the completion of this study, the Sponsor will 
continue to provide ATG-010 to patients with clinical benefits as needed (per Investigators’ 
judgment), and continue to collect safety data as reported. 
 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
40/84 
 
 
8. 
Selection of Patients 
8.1. 
Number of Patients 
A total of 82 patients will be enrolled. See Section 7.1. 
8.2. 
Inclusion Criteria 
Patients must meet all of the following inclusion criteria to be eligible to enroll in this study: 
1. Aware and sign the informed consent form (ICF) voluntarily. 
2. Age ≥ 18 years. 
3. Patients with multiple myeloma must have previously received regimens with 
immunomodulatory agent (lenalidomide) and proteasome inhibitor (bortezomib), are refractory 
to both drugs, and are refractory or intolerant to the most recent line of therapy (Patients 
documented as intolerant are allowed to be screened only after discussing and obtaining an 
approval from Sponsor Medical Monitor). Refractory MM includes primary refractory (patients 
do not achieve minimal response (MR) or have disease progression during therapy) or 
secondary refractory patients have progression within 60 days after completion of therapy). 
4. Any non-hematological toxicities (except for peripheral neuropathy as described in exclusion 
criterion #17) that are relevant to previous therapies must have resolved to ≤ Grade 2 prior to 
the first dose of study drug. 
5. Adequate hepatic function: total bilirubin <2× upper limit of normal (ULN) (for patients with 
Gilbert’s syndrome, a total bilirubin of <3× ULN is required), AST <2.5× ULN, and ALT <2.5× 
ULN. 
6. Adequate renal function: estimated creatinine clearance ≥20 mL/min (calculated using the 
formula of Cockroft-Gault). 
7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2. 
8. Measurable MM as defined by at least one of the following: 
a． Serum M-protein (by serum protein electrophoresis, SPEP) ≥5 g/L,  
b．24 hours-Urinary M-protein excretion ≥0.2 g (200 mg), 
c． Serum free light chain (FLC) ≥100 mg/L with abnormal FLC ratio.  
9. Adequate hematopoietic function (no platelet transfusions within 1 week, and no red blood cell 
transfusions within 2 weeks prior to screening examination): 
a． Hemoglobin level ≥80 g/L 
b．ANC ≥1000/mm3 (1.0×10 9/L)   
c． Percentage of plasma cells in bone marrow <50%, platelet count ≥75,000/mm3 (75×10 9/L); 
or percentage of plasma cells in bone marrow ≥50%, platelet count ≥50,000/mm3 (50×10 9/L). 
10. Female patients of childbearing potential must meet below two criteria: 
a． Female patients of childbearing potential must agree to use 2 methods of contraception 
acceptable by the study physician or complete sexual abstinence throughout the study, and 
for 3 months following the last dose of study treatment. 
i. 
Sexual abstinence: this method is acceptable when it is consistent with the 
patient’s preference and daily lifestyle. Periodic abstinence (based on calendar, 
ovulation, symotmatic body temperature, or post-ovulation methods) is not 
acceptable. 
ii. 
Acceptable contraception methods include: oral contraceptives, injectable 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
41/84 
 
 
contraceptives, or implanted sex hormonal contraceptives, intrauterine 
contraceptive device, barrier contraceptivse with spermicide; or a sexual partner 
who is status post of a sterilization surgery and using at least one barrier 
contraceptive tool. 
b．Must have a negative serum pregnancy test at screening.  
Note: Female patients of childbearing potential refer to all women who have started 
menarche and are not in the postmenopausal period and have not had surgical sterilization 
(for example hysterectomy, bilateral salpingectomy, and bilateral oophorectomy). 
Postmenopausal is defined as more than 12 consecutive months of amenorrhea for 
unspecified reasons. Women who are taking oral contraceptives or using mechanical 
contraceptive method such as intrauterine device are considered childbearing potential. 
11. Male patients (including those who have received vasectomy) must agree to use a condom if 
sexually active with a female of child-bearing potential from the date of signing the informed 
consent form (ICF), throughout the study, and for 3 months without pregnancy plan following 
the last dose of study treatment. 
8.3. 
Exclusion Criteria 
 Patients who meet any of the following criteria will not be enrolled: 
1. Asymptomatic (smoldering) MM. 
2. Plasma cell leukemia. 
3. Documented complicated with amyloidosis. 
4. Central nervous system (CNS) involved MM. 
5. Pregnancy or breastfeeding. 
6. Prior to the first dose of study drug: 
a． Chemotherapy within 1 week (including steroid therapy in chemotherapy regimen); 
b．Radiation, immunotherapy or other anti-MM therapy within 4 weeks; 
c． Radio-immunotherapy within 6 weeks. 
7. Graft versus host disease (after allogeneic stem cell transplantation). 
8. Life expectancy of < 4 months. 
9. Major surgery within 4 weeks prior to the first dose of study drug. 
10. Patients with active, unstable cardiovascular diseases, meet any of the following: 
a. Symptomatic ischemia;  
b. Uncontrolled clinically-significant conduction abnormalities (e.g., patients with ventricular 
tachycardia on antiarrhythmics are excluded; patients with first-degree atrioventricular (AV) 
block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) 
are allowed); 
c. Congestive heart failure (CHF) of New York Heart Association (NYHA) ≥ Grade 3; 
d. Acute myocardial infarction (AMI) within 3 months prior to the first dose of study drug. 
11. Uncontrolled hypertension (systolic blood pressure >140 mmHg or diastolic blood pressure >90 
mmHg). 
12. Uncontrolled active infection requiring treatment within 1 week prior to the first dose of study 
drug. 
13. Known HIV seropositive. 
14. Known active hepatitis A, B, or C infection; or known to be positive for HCV RNA or HBsAg 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
42/84 
 
 
(HBV surface antigen). 
Note: including HBsAg negative but hepatitis B cored (HBc) antibody positive with detectable 
hepatitis B virus deoxyribonucleic acid (HBV-DNA) level (the upper limit of normal for 
HBV-DNA testing is based on the test value of each center). 
15. Prior malignancy that required treatment or has shown evidence of recurrence (except for skin 
basal-cell carcinoma and the following in-situ carcinoma: squamous cell carcinoma, bladder 
cancer in situ, endometrial cancer in situ, cervical cancer in situ/atypical hyperplasia, 
accidental histological finding of prostate cancer (TNM staging is T1a or T1b), or breast cancer 
in situ) within 5 years prior to the first dose of study drug. 
16. Active GI dysfunction interfering with the ability to swallow tablets, or any GI dysfunction that 
could interfere with absorption of study treatment. 
17. Grade ≥3 peripheral neuropathy, and Grade ≥2 painful neuropathy, within 3 weeks prior to the 
first dose of study drug. 
18. Active psychiatric disorder, or organic disease which, in the opinion of the Investigator, is not 
suitable for the study. 
19. Participation in another investigational anti-cancer clinical trial within 3 weeks or within 5 
half-life (T1/2) time periods prior to the first dose of study drug. 
20. Receipt any following treatments prior to the first dose of study drug: 
a. Platelet infusion within 1 week; 
b. RBC transfusion within 2 weeks; 
c. Receipt of the following blood growth factors within 2 weeks: Granulocyte colony 
stimulating factor (G-CSF), granulocyte‑macrophage colony stimulating factor (GM-CSF), 
erythropoietin (EPO), megakaryocyte growth factor, and/or platelet stimulating factor. 
21. Known intolerance to or contraindication for glucocorticoid therapy. 
22. Prior exposure to a SINE compound, including ATG-010. 
 
8.4. 
Screening Failures 
An informed consent form will be signed; however, patients who fail to receive study treatment for 
any reason are defined as screen failure. For all screen failures, the Investigator will enter the 
screening number, patient’s initials, and reason for screen failure into the electronic Case Report 
Form (eCRF). Screen-failure patients will be replaced. Screen-failure patients can be re-screened. 
8.5. 
Study Patient Number 
Each patient will be allocated with an exclusive study number, which will be used throughout the 
study. The patient number will not be re-allocated or re-used, regardless of the reason. 
Screen-failure patients shall obtain the consent from the Sponsor Medical Monitor before 
re-screening. However, such patients will be allocated with a new patient number and marked it as 
re-screened. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
43/84 
 
 
9. Assessment Methods and Endpoints 
9.1. 
Standard Study Assessments 
All assessments should be carried out as described in Table 1. 
9.1.1. 
Demographics 
During the screening period, patients’ demographic data will be collected. These data include the year 
of birth, age, gender, race, and ethnic group. 
9.1.2. 
Medical History 
Each patient’s complete MM history and other important medical histories will be obtained. Medical 
history includes baseline symptoms, detailed history of prior MM therapies, and other prior anticancer 
therapies (i.e., transplant, chemotherapy, hormone therapy, immunotherapy, biotherapy, radiotherapy, 
and surgery) including the start and end dates, best efficacy, dates of disease progression (during or 
after therapy), and discontinuationsdue to intolerability or toxicity. Smoking history will be recorded. 
The Investigator should review these data prior to the dose on Cycle 1 Day 1. 
9.1.3. 
Concomitant Medications 
At each scheduled visit, each patient’s concomitant medications will be recorded. Medication history 
should be detailedly recorded in the eCRF. Thereafter, at each study visit, patients will be asked 
whether they have used any other drugs other than the study drugs (from screening to the end of 
study). All concomitant medications and changes in medication including dietary supplements, over-
the-counter, and oral herbal preparations should be recorded in the eCRF. There is no need to record 
routine anesthetics andcontrast agents that arerequired for diagnosis or surgical procedures. 
Supportive care (e.g., appetite stimulants, antiemetics, and antidiarrheals, etc.) is encouraged (see 
Section 11.4.2). 
9.1.4. 
Physical Examination 
A complete physical examination (PE), including vital signs (blood pressure, pulse, respiratory rate, 
and body temperature), will be carried out during Screening and the EoT visit. All other PEs during 
the study should be symptom directed. Any significant findings existed before the informed consent 
is signed must be recorded on the medical history page of the patient’s CRF. Significant new 
findingsincluding plasmacytomas which are benign or exacerbated after informed consent, must be 
recorded on the AE or plasmacytoma page of the patient’s CRF. 
Unless otherwise specified, PE includes the following items: 
• 
Body height (without shoes), unit: centimeter (cm), measured only at Screening 
• 
Body weight (with indoor clothing only, without shoes), unit: kilogram (kg) 
• 
Body temperature 
• 
Systolic blood pressure, diastolic blood pressure, and pulse 
• 
Physical examination of the whole-body systems 
Blood pressure information must be recorded in the source documents at the study site. Clinically 
relevant findings found after the initiation of treatment and complying with the definition of AE must 
be recorded in the AE eCRF. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
44/84 
 
 
9.1.5. 
ECOG Scoring 
ECOG scoring (see Appendix 1) will be carried out at Screening, Day 1 of each cycle, and the EoT 
visit. 
9.2. 
MM disease specific assessments 
Patient response is assessed according to the procedures summarized in Table 4 and staged according 
to the IMWG response criteria summarized in Table 10 (Appendix 3). Disease response will be 
uniformly assessed by the independent IRC (Section 7.2). 
According to IMWG, the quantitative Ig level measured by nephelometry can be used to replace the 
M-protein level measured by SPEP for patients with IgA or IgD myeloma. Besides, if a patient fails 
to provide the 24-hour urine sample after screening, the response profile will be confirmed per IMWG. 
At each study visit, all MM assessments specified in this study protocol should be carried out prior 
to dosing. If MM assessments are performed at unscheduled times, these results must be recorded as 
unscheduled visits in the eCRF. These assessments include SPEP, UPEP, serum FLC, β2 
microglobulin, quantitative Ig, and serum/urine protein immunofixation. 
The results of SPEP and serum protein immunofixation, quantitative Ig, serum FLC, and 24-hour 
UPEP with immunofixation must be recorded at each specified time point. A blood sample and a 
urine sample will be sent to the central laboratory at each time point. If the central laboratory results 
show achievement of CR or sCR, samples for subsequent MM disease assessment should be collected 
per IMWG and sent to the central laboratory for confirming the CR or sCR. At each time point, 
approximately 12.5 mL of blood and 24-hour urine should be collected and sent to the central 
laboratory. For detailed information, please refer to the Laboratory Manual. 
No matter what kind of diagnosis is currently adopted (for example, 24-hour UPEP must be collected 
at each time point specified in the study protocol, even though SPEP, Ig, or FLC is currently adopted 
for the patient), all diseases assessment (SPEP, UPEP, FLC, quantitative Ig, and serum/urine protein 
immunofixation) should be performed. 
Table 4:  Special Assessments of MM 
Procedure 
Notes 
SPEP and serum M-
protein 
level 
determination 
Per IMWG. 
UPEP (24-hr urine for 
total protein) and urine 
M-protein 
level 
determination 
Per IMWG. If a patient fails to provide the 24-hr urine sample, it should be recorded. Every 
effort should be made to collect 24-hr urine samples at the specified time points. 
The 24-hour urine sample collected must be performed with UPEP - other methods are not 
acceptable. 
UPEP must be performed at each time point specified in the study protocol, even if SPEP 
is adopted for the patient. 
Serum FLC 
Per IMWG. 
Quantitative Ig level 
Per IMWG. 
For IgA myeloma and IgD myeloma, quantitative Ig determination is preferred for disease 
assessment; the same variation rate should be adopted for serum M peaks. Only 
nephrlometryy can be used for response assessment, and SPEP and nephrlometry value 
cannot be used interchangeably. (Durie et al., 2006). 
β2 microglobulin 
For MM staging (Appendix 2), not for response assessment (for the local laboratory only) 
Skeletal survey 
Skeletal survey (by X-rays and/or other clinically appropriate imaging methods [MRI, 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
45/84 
 
 
Procedure 
Notes 
whole body CT, or PET/CT]) will be performed per Investigator’s discretion within 45 days 
prior to C1 D1, and if clinically indicated, may be performed per Investigator’s discretion 
during the study period. X-rays should include a lateral radiograph of skull, anteroposterior 
and lateral views of the spine, and anteroposterior views of the pelvis, ribs, femora, and 
humeri. 
The results will be interpreted by the local laboratory. 
If lytic bone lesions or plasmacytomas are observed at Screening, their number and size 
should be recorded in the CRF. Bone lesions and/or plasmacytomas seen at baseline should 
be assessed during the study period by the same imaging method adopted at screening, with 
the assessment frequency determined per Investigator’s discretion. 
• 
For patients without soft tissue plasmacytomas (i.e., bone lesions only), skeletal 
survey should be performed by X-rays or low-dose CT. Contrast radiography is 
not required. 
• 
For patients with soft tissue plasmacytomas, skeletal survey should be performed 
by X-rays or low-dose CT (contrast radiography not required) and MRI or CT or 
PET-/CT should be additionally performed, for which contrast enhancement is 
often required. 
Clinical plasmacytoma 
If detected by physical examination/palpation at screening, plasmacytomas should be 
counted and measured per IMWG guidelines, recorded, and later re-assessed and recorded 
during the symptom-directed physical examination. 
Bone marrow (BM) 
aspirate 
BM aspirate obtained at Screening will be used for MM (a) karyotyping and FISH analysis 
(performed in the central laboratory) to confirm diagnosis and classify MM sub-type. 
For patients with CR or sCR, BM aspirate will also be collected for exploratory MRD 
analysis (performed in the central laboratory). 
Efficacy assessment is performed according to the guidelines of the International Myeloma 
Working Group (IMWG) 
For detailed information, please refer to the Laboratory Manual. 
If clinically indicated, bone marrow core (trephine) biopsy will be performed to assess the 
response profile. 
Bone 
marrow 
core 
(trephine) biopsy 
This will be performed as soon as possible after confirmation of CR and sCR by serum and 
urine assessments (per IMWG). 
If serum and urine immunofixation is negative and any soft tissue plasmacytoma disappears, 
a tissue core biopsy must be performed to confirm CR and sCR. For detailed information, 
please refer to the Laboratory Manual. 
9.2.1. Bone Marrow Aspirate for MM Diagnosis and Classification and Efficacy Evaluation 
The 10 mL of bone marrow aspirate sample will be collected at Screening to assess type of MM and 
high-risk mutations (including del13, del(17p) translocation, t(14;16) translocation, t(4;14) 
translocation, and 1q21 amplification) in tumor cells. The central laboratory will perform FISH 
analysis to identify specific chromosome translocations at loci known to be rearranged in MM. For 
more information about these procedures, please refer to the Laboratory Manual. 
9.2.2. Bone Marrow Aspirate for MRD Analysis 
For patients who achieve CR or sCR, 5 mL of bone marrow aspirate sample will be collected at the 
time of response for exploratory minimal residual disease (MRD) analysis. For more information 
about these procedures, please refer to the Laboratory Manual. 
9.2.3. Bone Marrow Biopsy for Efficacy Confirmation 
This will be performed as soon as possible after confirmation of CR and sCR based on serum and 
urine assessments (per IMWG). If serum and urine immunofixation is negative and any soft tissue 
plasmacytoma disappears, a tissue core biopsy must be performed to confirm CR and sCR. For more 
information about these procedures, please refer to the Laboratory Manual. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
46/84 
 
 
9.3. 
Multiple Myeloma Response Criteria 
In this study, response is assessed per IMWG criteria (Kumar 2016) All MM assessments must be 
carried out at each time point specified in this study protocol (Table 1). 
Response will be assessed according to IMWG criteria for response assessment in MM (Appendix 3). 
The response must be confirmed using 2 consecutive samples. The time interval between samples 
can be discussed with Medical Monitor. Samples can be collected on the same day but must be 
analyzed independently. 
• Complete Response (CR) 
• Stringent Complete Response (sCR) 
• Very Good Partial Response (VGPR) 
• Partial Response (PR) 
• Minimal Response (MR) 
• Stable Disease (SD) 
• Disease progression (PD) 
9.4. 
Safety Evaluation 
Investigators should closely monitor patient’s vital signs (blood pressure, pulse, respiratory rate, and 
body temperature). During the trial, if the Investigator considers additional related examinations 
(e.g., ECG monitoring, pulmonary function monitoring) are required based on the patient’s condition, 
such examinations should be performed according to the routine clinical practice at the study site. 
The most common AEs in existing clinical trials are mainly hematological, gastrointestinal and 
systemic symptoms (fatigue, decreased appetite, and weight loss). Monitoring and risk control 
should be strengthened during the clinical trial. Investigators should also closely monitor 
drug-related effects that may occur, and strengthen the assessment and monitoring of adverse 
reactions in immune system and pancreas. For the safety data of ATG-010, please refer to the 
Investigator’s Brochure. 
Safety evaluation will be performed at each visit. Procedures included in the safety evaluation are 
summarized as follows. 
9.4.1. 12 Lead ECG 
As shown in Table 1, standard 12-lead ECG will be performed. The Investigator will interpret ECG 
according to the following categories: normal, abnormal but not clinically significant, or abnormal 
and clinically significant. The date and time of ECG and parameters below should be recorded in 
the eCRF: heart rate, PR interval, QT interval, QRS interval, and corrected QT interval (QTc) 
calculated by Bazett’s formula or Fridericia’s correction formula (Bazett 1920, Fridericia 1920). If 
Bazett’s correction formula is entered by the study site, Fridericia-corrected QTc interval (QTcF) 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
47/84 
 
 
will be deduced using the following formula: QT/(RR^[1/3]), where, RR = 60/heart rate. 
9.4.2. Clinical Laboratory Assessments 
As shown in Table 1, the following clinical laboratory tests should be performed. 
• Hematological tests, which contain complete blood count (CBC) and differential, 
including red blood cell (RBC) count, hemoglobin, hematocrit, white blood cell (WBC) 
count and absolute differential (neutrophils, lymphocytes, monocytes, eosinophils, and 
basophils), and platelet count. 
• Serum chemistry (blood sample: serum) 
− Complete serum chemistry includes blood sodium, blood potassium, chloride, 
bicarbonate (HCO3-)*, blood urea nitrogen (BUN)/blood urea (Urea), creatinine, 
blood glucose, blood calcium, blood phosphorus, blood magnesium, aspartate 
aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT), lactate 
dehydrogenase (LDH), alkaline phosphatase, bilirubin total bilirubin, total protein, 
albumin, amylase, lipase**, creatine kinase, and uric acid. 
− Limited serum chemistry includes blood sodium, blood potassium, chloride, 
bicarbonate*, BUN/Urea, creatinine, blood glucose, ALT, AST, alkaline phosphatase, 
total bilirubin, and LDH, unless otherwise indicated clinically. 
• Thyroid-stimulating hormone (TSH). 
• Viral serology is performed at Screening, including HBsAg, HBsAb, HBcAb, HBV-
DNA (eg, negative for HBsAg and positive for HBcAb), HCVAb, HCV-RNA (eg, 
positive for HCVAb), and HIV. If HBsAg is negative but anti-HBc is positive at 
screening, HBV-DNA must be tested and then every subsequent cycle (i.e., every 4 
weeks). 
• Coagulation parameters include prothrombin time (PT), international normalized ratio 
(INR), and activated partial thromboplastin time (aPTT). 
• Urinalysis includes bilirubin urine, glucose urine, urine occult blood/urine red blood cells, 
ketone bodies, pH, urine protein, urine specific gravity, and urobilinogen. 
* Bicarbonate is optional in the absence of safety concerns. In the presence of safety concerns, study 
sites that are not eqippted bicarbonate testing can select venous blood carbon dioxide binding 
capacity or arterial blood gas analysis with similar clinical significance as an alternative test, or 
perform examination items that are considered appropriate and necessary by the Investigator. 
** Study sites that are not equipped for lipase testing can accept test results from another hospital 
(any hospital certified by the Ministry of Health). 
All the tests above will be analyzed by the local laboratory at each study site and the laboratory test 
reports will be provided to the Investigator. The Investigator or designee will review the laboratory 
results and assess the clinical significance of all abnormal values. Appropriate measures should be 
taken for any abnormal values of clinical significance, until the condition is stabilized or the 
laboratory test value returns to a level within the clinically acceptable range regardless of the 
relationship with the study drug) or baseline level. Any laboratory test value that remains to be 
abnormal at the EoT visit or any laboratory test value that is considered clinically significant should 
be followed up for 30 days or until the abnormality disappears or returns to the baseline level 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
48/84 
 
 
according to the established medical standard. Toxicity will be assessed by adopting CTCAE v4.03. 
9.4.3. Pregnancy Test 
For females of childbearing potential; negative serum human chorionic gonadotropin (hCG) 
pregnancy test must be obtained within 3 days before the first dose of study treatment. Pregnancy 
testing (serum hCG or urine) is also required for females of childbearing potential prior to dosing on 
Day 1 of Cycles ≥ 2 and at the EoT Visit (serum hCG). 
Pregnancy testing may also be performed as clinically indicated during the study. 
9.5. 
Pharmacokinetic 
9.5.1. PK Sampling Points 
Blood sampling (3 mL/sampling point) for PK analysis will be completed on Day 1 and Day 15 of 
Cycle 1, including a total of 26 sampling points. The specific time points are as follows: 
Pre-dose: 0-10 min 
Post-dose: 30 min ± 5 min, 1 hour ± 10 min, 1.5 hours ± 10 min, 2 hours ± 10 min, 3 hours ± 10 min, 
4 hours ± 20 min, 5 hours ± 20 min, 6 hours ± 20 min, 8 hours ± 20 min, 10 hours ± 20 min, 24  hours 
± 20 min, and 48 hours ± 20 min.  
Approximately 3 mL of whole blood will be collected at each sampling point and sent to the central 
laboratory for testing. 
9.5.2. 
Pharmacokinetic Endpoints 
PK blood samples will be collected from 15 patients enrolled. PK analysis of ATG-010 plasma level 
will be performed on the blood samples collected. The PK endpoints evaluated include but are not 
limited to the ATG-010 maximum serum concentration (Cmax) and time to maximum serum 
concentration (tmax). See Section 13.3.5 for details. 
 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
49/84 
 
 
10. 
Study Discountinuation Criteria 
10.1. 
Premature Termination of Study 
This study may be terminated for any reasons, including medical reasons or ethical reasons that affect 
the continued conduct of the study, or difficulty in recruiting patients, at the discretion of the Sponsor. 
If a safety signal is identified, the Investigator/designee should notify the Sponsor (see Section 7.2). 
However, Sponsor should decide in conjunction with the regulatory authorities whether this trial 
should be modified or terminated. If this occurs Sponsor should notify the IRB/REB/EC and 
Investigators. 
10.2. 
Premature Termination of Study by Individual Patients 
Investigator may exclude a patient from study treatment at his/her discretion for any of the following 
reasons: 
• Progressive disease defined per IMWG based on MM progression, including a 
confirmatory analysis for proving the progression. Progressive disease should be 
confirmed by the IRC before the study treatment is discontinued. 
• Unacceptable AE or intolerance to study treatment. 
• Patient decides to discontinue study treatment. 
• Any medically applicable reason or major study protocol violation per Investigator 
discretion. 
The reason for study termination must be clearly recorded in the source documents and study CRF 
including the reasons for patient consent withdrawal and Investigator’s decision to terminate the 
patient’s study participation. 
Patients may discontinue study treatment for any reasons. Patients who elect to discontinue study 
treatment should be encouraged to stay in the study, so that follow-up information on disease 
progression and survival status can be obtained. However, patients can elect to withdraw consent and 
decline further participation in this trial. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
50/84 
 
 
11. Treatment 
The dosage form to be adopted for ATG-010 study drug is an immediate-release coated tablet for oral 
administration. ATG-010 tablets are single strength (20 mg) tablets and are supplied in a billfold-sized 
blister package. Dexamethasone 20 mg will be given with each dose of ATG-010. 
See Section 11.1.3 for more information. 
11.1. 
Dosage and Administration 
11.1.1. 
Dose Adjustment 
Before any change to the dose, all dose modifications will be discussed/decided by the Investigator 
and the Sponsor’s Medical Monitor. 
11.1.2. 
Label 
All drug packages will be labeled according to the requirements of current GCP and regulatory 
authorities. The drug label contains the drug name, storage conditions, and batch number, etc. 
11.1.3. 
TREATMENT INFORMATION 
Patients will take a fixed oral dose of ATG-010 80 mg plus dexamethasone (20 mg) twice weekly. 
The drugs should be taken twice each week at a fixed time (whenever possible), with a dose interval 
of approximately 48 hours (e.g., Monday and Wednesday or Tuesday and Thursday, etc.). Each 
treatment cycle will last 4 weeks. Patients are allowed to take the drugs home to administrate. 
Patients who are partially intolerant to glucocorticoids (determined by the Investigator) are allowed 
to use the minimum dose of dexamethasone (10 mg). If any patient fails to tolerate this dose, drug 
discontinuation or further dose reduction may be allowed after the Investigator has a discussion with 
the Sponsor’s Medical Monitor based on the specific situation. Dexamethasone will be provided in 
the form of tablet and can be taken home. 
The drugs should be taken with at least 120 mL of liquid (water, milk, juice, etc.) within 30 minutes 
after solid food cousumption. For detailed information on the drug formulation, preparation and 
administration, please refer to Appendix 4. 
ATG-010 tablets should be swallowed whole and shall not be crushed. 
The Investigator or representative will assess the study treatment compliance at each patient’s visit, 
and record it together with the patient with drug counts in the source documents. The date will be 
recorded according to the study drug schedule. Investigator or designee will compare the number of 
tablets dispensed against the number returned by the patient. Any deviations and missed doses should 
be recorded in the eCRF and drug accountability logs, so that they can be verified with the reasons. 
The Investigator/designee should make efforts to ensure full compliance with the dosing schedule 
and provide guidance to patients in a timely manner. 
11.1.4. 
Dosage Adjustments in Patients with VGPR 
In order to improve long-term disease control and tolerability, dose reduction in patients with a very 
good antitumor activity of ATG-010 is allowed by this study protocol. Therefore, for patients with 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
51/84 
 
 
≥ VGPR lasting for ≥ 6 months and whom the Investigator believes may benefit from dose reduction, 
the following dose reductions may be considered after the Sponsor’s Medical Monitor is consulted: 
(a) the dose of dexamethasone may be reduced by 40%, or (b) the dose of ATG-010 may be lowered 
by 1 level, or (c) the dosing frequency may be reduced to once weekly. Normally, dexamethasone 
should always be given on the day of ATG-010 dosing. Patients who receive dose reduction according 
to this protocol should have appropriate MM tumor assessment labs being monitored at least once 
every 2 weeks (e.g., FLC), so that the dose may be re-escalated to their initial dose when evidence of 
disease progression appears. These monitoring studies may be done at local laboratories. 
11.1.5. 
Guidelines for Dose Reduction due to Toxicity 
Toxicity will be graded according to CTCAE v4.03 criteria; these grades of severity are applicable to 
the treatment adjustments described below. 
If two or more toxicities occur at the same time, dose modification will be determined based on the 
highest grade of severity. 
As described in each section of applicability to the specific toxicities, re-escalation of study drug dose 
is allowed. If the treatment is delayed by more than 28 days due to drug-related toxicity, patient’s 
study protocol treatment may be canceled. 
All dose modifications or treatment delays must be documented in the electronic case reporting form 
(eCRF) and corresponding reasons must be provided. 
According to the observationsfrom the ongoing Phase 1 study in patients with advanced hematologic 
malignancies and solid tumors, ATG-010 has a very wide therapeutic range with activities from 
approximately 6 mg/m2 to ≥60 mg/m2. Therefore, in order to ensure the best specific anti-tumor 
activity and tolerability in patents, dose reduction and/or modification of schedule are allowed, as 
shown in Table 5 and Table 6. Patients should also be actively treated with supportive care to reduce 
toxicities. 
For all grade ≥3 hematological and non-hematological AEs that are unrelated to ATG-010, after 
discussion with the Sponsor’s Medical Monitor and at the discretion of the Investigator, the dose of 
ATG-010 may be maintained if the patient can continue the oral administration. 
Table 5:  Pre-specified Dose/Schedule Modification for AEs Related to Study Drug 
Dosage 
Level(s) 
ATG-010 Dose Administered 
Starting 
dose 
0 
80 mg BIW (total dose: 160 mg per week) 
Dose 
reduction 
-1 
100 mg QW 
-2 
80 mg QW 
-3* 
60 mg QW 
* If the Investigator believes further dose reduction could still benefit the patient, a decision can be made through 
discussion with the Sponsor ‘s Medical Monitor. 
Table 6:  Guidelines for Supportive Care and Dose Modification 
Please pay attention to the following suggestions: 
• For all hematological or non-hematological AEs unrelated to ATG-010, the dose of 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
52/84 
 
 
ATG-010 may be maintained per the Investigator’s discretion after the Sponsor’s 
Medical Monitor is consulted. 
• For all AEs related to ATG-010, if stable disease is maintained ≥4 weeks by the 
prescribed dose reduction/interruption in Table 6, dose re-escalation may be considered 
after approval by the Sponsor’sMedical Monitor. 
Adverse Reaction a 
Occurrence, 
count 
Action 
Hematological adverse reactions 
Thrombopenia 
Platelets count 25,000 to < 
75,000/m3 
Any 
• 
Lower the dose of ATG-010 by 1 level (see Table 5). 
Platelets count 25,000 to < 
75,000/m3, with concomitant 
hemorrhage 
Any 
• 
Interrupt ATG-010. 
• 
After recovery from hemorrhage, lower the dose by 1 level 
and re-initiate ATG-010 administration (see Table 5). 
Platelet count < 25,000/m3 
Any 
• 
Interrupt ATG-010. 
• 
Monitor platelet count, until it is restored to a level of at 
least 50,000/m3. 
• 
Lower the dose by 1 level and re-initiate ATG-010 
administration (see Table 5). 
Neutropenia 
Absolute neutrophil count 0.5 to 
1.0 × 109/L, without fever 
Any 
• 
Lower the dose of ATG-010 by 1 level (see Table 5). 
Absolute neutrophil count ＜
0.5 
× 
109/L 
or 
febrile 
neutropenia 
Any 
• 
Interrupt ATG-010. 
• 
Continuously monitoring neutrophil count, until it is 
restored to ≥1.0 × 109/L. 
• 
Lower the dose by 1 level and re-initiate ATG-010 
administration (see Table 5). 
Anaemia 
Hemoglobin < 8.0 g/dL 
Any 
• 
Lower the dose of ATG-010 by 1 level (see Table 5). 
• 
Blood transfusion and/or adopting other therapies in 
clinical guidelines. 
Life-threatening 
consequences 
(urgent intervention indicated) 
Any 
• 
Interrupt ATG-010. 
• 
Continuously monitor hemoglobin, until it is restored to a 
level ≥ 8 g/dL. 
• 
Lower the dose by 1 level and re-initiate ATG-010 
administration (see Table 5). 
• 
Blood transfusion and/or adopting other therapies in 
clinical guidelines. 
Non-hematological adverse reactions 
Hyponatremia 
Sodium level ≤ 130 mmol/L 
Any 
• 
Interrupt ATG-010 and give appropriate supportive care. 
• 
Continuously monitor sodium level, until it is restored to 
≥ 130 mmol/L. 
• 
Lower the dose by 1 level and re-initiate ATG-010 
administration (see Table 5). 
Fatigue 
Grade 2 (lasting more than 7 
days) or grade 3 
Any 
• 
Interrupt ATG-010. 
• 
Continuously monitor, until fatigue is resolved to grade 1 
or baseline level. 
• 
Lower the dose by 1 level and re-initiate ATG-010 
administration (see Table 5). 
Nausea and vomiting 
Grade 1 or 2 nausea (oral intake 
reduced without manifest body 
weight loss, dehydration, or 
malnutrition), or, grade 1 or 2 
Any 
• 
Continue ATG-010 administration, and initiate additional 
anti-nausea administration. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
53/84 
 
 
Adverse Reaction a 
Occurrence, 
count 
Action 
vomiting (not more than 5 times 
per day) 
Grade 3 nausea (insufficient oral 
intake of energy or liquid), or, 
grade 3 or above vomiting (not 
less than 6 times per day) 
Any 
• 
Interrupt ATG-010. 
• 
Continuously monitor, until nausea or vomiting is 
resolved to grade 2 or below or baseline level. 
• 
Initiate additional anti-nausea administration. 
• 
Lower the dose by 1 level and re-initiate ATG-010 
administration (see Table 5). 
Diarrhea 
Grade 
2 
(daily 
defecation 
increased by 4 to 6 times 
compared to baseline) 
First time 
• 
Continue ATG-010 administration, and give supportive 
care. 
 
Second and 
subsequent 
• 
Lower the dose of ATG-010 by 1 level (see Table 5). 
• 
Give supportive care. 
Grade 3 and above (daily 
defecation increased by 7 or 
more 
times 
compared 
to 
baseline; 
hospitalization 
indicated) 
Any 
• 
Interrupt ATG-010 and give supportive care. 
• 
Continuously monitor, until diarrhea is resolved to grade 
2 or below or baseline level. 
• 
Lower the dose by 1 level and re-initiate ATG-010 
administration (see Table 5). 
Weight loss and anorexia 
Body weight decreased by 10% 
to < 20%, or, anorexia with 
manifest 
weight 
loss 
or 
malnutrition 
Any 
• 
Interrupt ATG-010 and give supportive care. 
• 
Continuously monitor body weight, until it is restored to 
more than 90% of baseline body weight. 
• 
Lower the dose by 1 level and re-initiate ATG-010 
administration (see Table 5). 
Other non-hematological adverse reactions 
Grade 3 or 4 (life-threatening) 
Any 
• 
Interrupt ATG-010. 
• 
Continuously monitor until the reaction is resolved to 
grade 2 or below, lower the dose by 1 level and re-initiate 
ATG-010 administration (see Table 5). 
 
11.1.5.1. ATG-010 Dose Reduction due to Decreased Glomerular Filtration Rate  
ATG-010 is not mainly eliminated by kidney; therefore, there is no need to change the dose of 
ATG-010 in the presence of kidney dysfunction; however, creatinine clearance must be >20 mL/min, 
otherwise ATG-010 plus low-dose dexamethasone treatment cannot be initiated. If creatinine 
clearance is decreased during the treatment period and is considered unrelated to ATG-010, the dose 
of ATG-010 may be maintained, but patient’s condition must be closely monitored. If creatinine 
clearance is decreased to < 20 mL/min, it is considered to be related to ATG-010, and then the dose 
of ATG-010 should be lowered by 1 level. If creatinine clearance is restored to >20 mL/min and stays 
at this level for 4 weeks, the dose of ATG-010 can be restored to the previous level. If dialysis is 
given during the ATG-010 plus low-dose dexamethasone treatment period, ATG-010 plus low-dose 
dexamethasone must be given after dialysis. 
11.1.5.2. Adjustment of ATG-010 Dose in the Presence of Infection 
Any patient with grade ≥ 3 infection should interrupt ATG-010, until the infection is clinically 
resolved or the patient is clinically stable, and then ATG-010 administration can be re-initiated by 
lowering 1dose level. If the Investigator assesses that the infection is unrelated to the study drug and 
decide the administration of study drug can be continued, this decision should be made per 
discussion with the Sponsor’s Medical Monitor. 
Dexamethasone should be adjusted according to the guidelines of the medical institution, with 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
54/84 
 
 
adrenal suppression being taken into account. Missed doses shall not be made up. While re-initiating 
ATG-010 regimen, patients can continue long-term treatment with antibiotics or other antimicrobial 
agents per the Investigator’s discretion. 
11.1.5.3. Cases not Requiring ATG-010 Dose Reduction 
Below are exceptional cases to the dose modification guidelines. There is no need to interrupt 
ATG-010 in the following cases: 
• Any grade of alopecia 
• Electrolyte or serum analyte (e.g., urate) abnormalities that can be reversed by standard 
intervention 
11.1.5.4. Dose Modification to Missed Dose or Vomiting 
Note: A maximum of 2 ATG-010 doses can be given per week. 
Missed Dose 
If a dose is missed, the treatment schedule of the week should be modified to adapt to the 2 doses of 
the week, and 2 consecutive doses should be at least 36 hours apart. 
If this dose must be skipped (for example, per attending doctor’s advice), the next dose should be 
taken according to the treatment schedule. The dosing interval should not be less than 36 hours, and 
all missed doses and delayed doses should be recorded. 
Vomited Dose 
If vomiting occurs ≤ 1 hour after dosing, another dose should be taken. If vomiting occurs > 1 hour 
after dosing, the patient will be regarded as having taken a full dose. 
11.2. 
Study Drug Storage 
ATG-010 tablets should be stored in a safe area with access only to the study site personnel 
pharmacists or designees, at a temperature no more than 30°C (i.e., room temperature or refrigerating 
temperature). Room temperature storage is preferred. The tablets should not be frozen. Study sites 
need to record the temperature of the storage place for the study drugs. 
ATG-010 tablets (20 mg) are supplied in plastic blister packs with an aluminum foil lid. For detailed 
information on the preparation, storage, stability, and administration of ATG-010, see Appendix 4. 
Dexamethasone tablets should be stored according to the suggestions in the package inserts. 
11.3. 
Study drug Accountability 
The Investigator or designee must record the count and dispensing of study treatment drugs in the 
drug record log. Patients need to return all unused study treatment drugs and packages on a regular 
basis, at the end of study, or upon discontinuation of study treatment. During study site visits and at 
the completion of study, Clinical Research Associate (CRA) should check the drug count 
periodically. 
During the course of the study and at study close out, the Investigator should return all used and 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
55/84 
 
 
unused study treatment drugs as well as a copy of the completed drug record log to the Sponsor. 
ATG-010 shall not be used for any purposes outside the scope of this study protocol, nor shall it be 
transferred or licensed to any party not participating in this clinical study. The data of ATG-010 are 
proprietary confidential information, and the Investigator should keep it in this way. 
The Investigator or a responsible party designated by the Investigator must carefully record the 
inventory and disposition of unused materials. 
Before being used or returned to Antengene or destroyed by the designee, all drug supplies provided 
by Antengene must be stored in an appropriate safe place with limited access. The drug supplies 
must be counted and verified at the study site before being returned. Study sites need to maintain a 
temperature log of the storage place for the study drugs. 
11.4. 
Concomitant therapies 
11.4.1. 5-HT3 Antagonists Required 
Unless contraindicated, all patients should receive 5‑hydroxytryptamine (5-HT3) antagonists (e.g., 
palonosetron or equivalent) before the first dose of ATG-010 to minimize nausea. Alternative 
antiemetic agents may be used if the patient does not tolerate 5-HT3 antagonists. 
11.4.2. Supportive Care 
During the period of participatioing in this clinical trial, supportive measures should be taken to 
ensure the best medical care for patients. It is advised that patients maintain sufficient intake of 
liquids and calories during the course of treatment. Intravenous fluids therapy may be considered for 
patients at risk of dehydration. Patients will also receive blood product transfusions, antimicrobials, 
and growth factors including granulocyte colony-stimulating factors (for neutropenia), 
erythropoietins (for anemia,) and/or platelet-stimulating factors (for thrombocytopenia) as the best 
supportive treatment. 
In addition to dexamethasone included in the standard treatment plan and required 5-HT3 
prophylaxis (Section 11.4.1), the following supportive care (including anti-nausea/antiemetic 
therapy), antacids (proton pump inhibitors [PPIs] and/or H2 blockers), and other therapies may also 
be given: 
• Appetite stimulants: Megestrol acetate, at a dose of 80-400 mg per day. 
• Centrally acting preparations: Olanzapine, 2.5-5.0 mg per night by oral is recommended. 
• Neurokinin 1 receptor antagonists (NK1R antagonists): Aprepitant or equivalent may be 
considered, covering selected patients with severe nausea and vomiting. 
Additional anti-nausea and anti‑anorexia agents may be given as needed (per National 
Comprehensive Cancer Network® [NCCN] Clinical Practice Guidelines® for Antiemesis, NCCN 
Clinical Practice Guidelines® for Palliative Care and Chinese Expert Consensus on Prevention and 
Treatment of Nausea and Vomiting Related to Anti-Cancer Drug Treatment (2019 version)). 
11.4.3. Infection 
In patients with fever or other signs of systemic infection, appropriate broad-spectrum intravenous 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
56/84 
 
 
antibiotics and antifungals should be initiated immediately. 
11.4.3.1. Other Glucocorticoid Side Effects 
The management of common glucocorticoid side effects has been detailedly recorded. In this study, 
it is strongly recommended to actively use proton pump inhibitors (PPIs), anti-hypertensives, and 
other preparations, so that the combined use of dexamethasone plus ATG-010 can be continued. 
Patients with documented osteopenia or osteoporosis should continue to use dexamethasone with 
ATG-010 according to the requirements of this study. Standard precautionary measures should be 
formulated, for example, use of bisphosphonates, unless contraindicated. 
11.4.4. Concomitant Medications and Therapies 
Concomitant medications refer to any prescription drugs or over-the-counter preparations for 
prophylactic or therapeutic purposes, including vitamins, dietary supplements, over-the-counter 
medications, and oral herbal preparations. Patients can continue taking baselines drugs previously 
taken. All concomitant medications must be recorded in the eCRF (except for diagnostic or surgical 
preparations). Any diagnostic, therapeutic or surgical procedures performed during the study period 
should be recorded, including the dates, operating procedures, and any clinical findings (if 
applicable). 
11.4.4.1. Concomitant Medications Allowed 
Concomitant medications can be used for managing symptoms, AEs, and intermittent diseases, and 
if medically necessary, can be used as standard of care. Medications for treating concomitant 
diseases such as diabetes mellitus, hypertension, and etc. are allowed. 
11.4.5. Restricted Medications 
Medication:  
Theoretically, ATG-010 interacts with glutathione (GSH); therefore, the use of 
acetaminophen (Paracetamol) plus ATG-010 was limited in previous ATG-010 
studies. However, no significant clinical or laboratory abnormalities were found by 
the ongoing clinical safety evaluation on the combined use of these drugs [up to 1 
g of acetaminophen and up to 55 mg/m2 (about 80-100 mg) of ATG-010]. 
Accordingly, there is no longer any restrictions on the combined use of 
acetaminophen or acetaminophen-containing drug with ATG-010, except that 
acetaminophen must not exceed a total daily dose of 1 g on the dosing days of 
ATG-010. 
Diet:  
There is no dietary restriction in this study. Patients should maintain sufficient 
intake of calories and liquids. 
11.4.6. Prohibited Medicines 
Concurrent therapy: Concurrent therapy with any anticancer therapy drugs other than the study 
drugs is not allowed. Other investigational drugs shall not be used during the study. 
Any immunosuppressant use during the study period must be confirmed by the 
Medical Monitor. 
Medication:  
In this study, patients shall not use any drugs containing glutathione (GSH), 
S-adenosyl methionine (SAM), or N-acetylcysteine (NAC), since they may 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
57/84 
 
 
promote ATG-010 metabolism. See Appendix 5 for the list of representative drugs. 
In this study, patients must report all prescription and over-the-counter drugs to the 
doctor. 
11.4.7. Contraception Requirements 
During the study period, patients shall not get pregnant or father a child, since the study treatmenst 
in this study will affect the fetus. Women shall not breastfeed during the study period. Patients should 
be aware of that contraceptive measures must be taken while on the study; this is extremely important. 
Female patients of childbearing potential must agree to use 2 contraceptive methods (1 highly 
effective contraceptive method and 1 effective contraceptive method) and have a negative serum 
pregnancy test at Screening. Male patients, if sexually active with females of childbearing potential, 
must adopt an effective barrier method of contraception. Highly effective contraceptive methods 
include: 
1. Hormonal contraceptives (e.g., compound oral contraceptives, contraceptive patch, vaginal 
ring, injectable contraceptives, and implantable contraceptives) 
2. Contraceptive ring or intrauterine device 
3. Vasectomy or tubal ligation 
Effective contraceptive methods include: 
1. Barrier contraception (e.g., male condom, female condom, cervical cap, contraceptive 
diaphragm, and contraceptive sponge) 
It should be particularly noted that, 
• A barrier method of contraception itself alone cannot be used as highly effective 
contraception. 
• Correct use of contraceptive diaphragm or cervical cap, including use of spermatocide, 
is one kind of barrier method of contraception. 
• Cervical cap and contraceptive sponge are not very effective in parous women. 
• Use of spermatocide alone is not an appropriate barrier mehod of contraception. 
• Male condom plus cervical cap, contraceptive diaphragm or sponge with spermatocide 
(double-barrier method of contraception) is acceptable, but not a highly effective 
contraception. 
• Male condom and female condom shall not be used simultaneously, otherwise they may 
be teared up or damaged. 
In other words, the following contraceptive requirements should be met: 
1. Permanently surgically sterilized or post-menopausal sex partner 
2. Complete (real) sexual abstinence (when satisfying patient’s preference and daily lifestyle) 
is an acceptable method of contraception. Note: Periodic abstinence (e.g., calendar method, 
ovulation period method, symptothermal method, and post-ovulatory contraception) and 
coitus interruptus are not acceptable. 
Acceptable contraceptive methods must be explained to potential male and female patients. atients 
must agree to use the contraceptive methods described above throughout the study period and for 3 
months after the last dose of study treatment, otherwise they will not be eligible for participating in 
this study. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
58/84 
 
 
For more safety information about pregnancy, please see Section 4.31. 
11.4.8. Radiation Therapy 
If clinically indicated, palliative radiotherapy for non-target lesion(s) are permitted, however, the 
study drugs should be held for ≥1 day prior to initiation of palliative radiotherapy and ≥1 day after 
each dose of palliative radiotherapy. ATG-010 treatment shall not be terminated solely due to 
palliative radiotherapy. 
11.5. 
Treatment Compliance 
Investigator or other study personnel should supervise the study drug treatment administered in the 
study site and guide patients on study drug self-administration. Patients will be asked to bring their 
study drug packages at each visit, and their compliance with the study drug intake specified in the 
protocol will be checked by tablet count. 
After discussing with the patient and drug counting staff, the study personnel will record the 
compliance of study drug. The Investigator or designee will assess the compliance of study drug and 
record it in the source documents. The date will be recorded according to the study drug schedule. 
The Investigator or designee will count the number of dispensed tablets against the number of tablets 
returned by patient. Any dose deviations and missed doses will be recorded in the eCRF and drug 
accountability log to confirm the corresponding reason. 
 
 
 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
59/84 
 
 
12. 
Adverse Event 
An AE is any untoward medical occurrence in a patient or clinical study subject administered with a 
certain pharmaceutical product, irrespective of its causal relationship with the treatment. An AE can 
therefore be any unfavorable and unintended sign (e.g. an abnormal laboratory finding), symptom, or 
disease temporally associated with the use of an investigational product, whether or not related to the 
investigational product. 
It is expected that, clinically significant symptoms and signs associated with disease progression will 
be reported as AE; however, disease progression that is asymptomatic or confirmed by examinations 
only does not neede to be reported as an AE. 
All SAEs will be recorded since the subject signs the informed consent form. AEs will be recorded 
after the use of study drug till 30 days after the last dose. Any SAE learned by the Investigator at any 
time thereafter and suspected to be related to the study drug will also be recorded. 
Any abnormal laboratory finding or test result (e.g., PE, ECG, Echo, vital signs, etc.) occurring during 
treatment, if clinically significant (i.e., meeting any one or more of the following conditions), should 
be recorded as a single diagnosis on the AE page of the eCRF. 
1. 
Is accompanied by clinical symptoms 
2. 
Leads to a change of study drug (e.g., dose modification, interruption, or permanent 
discontinuation) 
3. 
Requires a change of concomitant therapy (e.g., addition, interruption, termination, or any other 
changes of concomitant medications, therapies or treatment). 
Investigator is responsible for recording all AEs occurring during the study period. Patients will be 
asked a non-directive question, for example, “Since our last inquiry/since the last visit, have you 
experienced any new symptoms or are there any changes in the symptoms?” AE should be reported 
on the corresponding page of the eCRF. 
The actual grade and duration of AE should be reported. 
The severity/intensity of AE will be graded based on subject’s symptoms per current Common 
Terminology Criteria for Adverse Events (CTCAE, v4.03). 
AEs that are not included in the CTCAE will be assessed according to the following criteria: 
• 
Grade 1 = transient or mild discomfort; activity not limited; no medical 
intervention/therapy required; 
• 
Grade 2 = mild-to-moderate or moderate limitation in activity, some assistance possibly 
required; no or minimal medical intervention/therapy required; 
• 
Grade 3 = moderate to marked limitation in activity, some assistance usually required; 
medical intervention/therapy required, hospitalizations possible; 
• 
Grade 4 = Life threatening - extreme limitation in activity, significant assistance required; 
significant medical intervention/therapy required, hospitalization or hospice care probable; 
• 
Grade 5 = death - the event results in death. 
The term “severe” is used to describe the severity of AE; the event itself may have little clinical 
significance (e.g., “severe” headache). This is different from “serious”. The seriousness of AE is 
based on its outcome and is usually associated with events posting a threat to patient’s life or functions. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
60/84 
 
 
Investigator will make judgments on the correlation between AE and study drug, as shown in Table 
7 below. 
Table 7:  Classification of AEs Listed Per Causal Relationship 
Not Related 
The event is not temporally associated with the study treatment, or by providing any other drug, 
therapeutic intervention, or underlying disease that can fully explain the event, the assessment of 
causality rules out the possibility of a reasonable causal relationship. 
Related 
The temporal association between the event and study treatment constitutes a definite causal 
relationship, and compared to any other drug, therapeutic intervention, or underlying disease, the 
event may be more reasonably explained by the exposure to study treatment. 
12.1. 
Serious Adverse Event 
A serious adverse event (SAE) refers to any untoward medical occurrence that at any dose (including 
those after the signing of ICF and prior to dosing): 
• 
Results in death 
• 
Is life-threatening (patient is at immediate risk of death at the time the event occurs) 
• 
Requires hospitalization (official hospitalization for medical reason) or prolongation of existing 
hospitalization 
• 
Results in permanent or significant disability/incapability 
• 
Results in a congenital anomaly/birth defect 
Important medical events that may not result in death, are not life-threatening, or do not require 
hospitalization may be considered SAEs when, based upon appropriate medical judgment, they may 
jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes 
listed in this definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not 
result in inpatient hospitalization, or the development of drug dependency or drug abuse. 
TEAE-unrelated hospitalizations due to elective procedures or other medical procedures during 
treatment will not be regarded as SAEs. 
Sudden death and death unexplained should be reported as an SAE. 
Progression of malignancy (including lethal outcomes) during the study period or within the safety 
reporting period should not be reported as an SAE. 
Hospitalizations due to the following events will not be regarded as SAEs: 
• 
Routine treatment or monitoring of the indications studied, is not related to any conditions 
aggravated. 
• 
Blood or platelet transfusion for routine treatment of the indications studied; however, 
hospitalization or prolongation of existing hospitalization due to complications of transfusion 
should still be reported as an SAE. 
• 
Procedures related to study protocol/disease-related examinations (e.g., surgery, scan, 
endoscopy, sampling for laboratory tests, bone marrow sampling). However, hospitalization or 
prolongation of existing hospitalization due to complications of these procedures should still be 
reported as an SAE. 
• 
Hospitalization or prolongation of existing hospitalization for technical, practical or social 
reasons in the absence of an AE. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
61/84 
 
 
• 
Pre-defined procedures (i.e., scheduled prior to initiation of study treatment); must be recorded 
in the source documents. However, hospitalization or prolongation of existing hospitalization 
due to complications should still be reported as an SAE. 
• 
Elective treatment for an existing sickness that is unrelated to the indications studied. 
12.1.1. Follow-up of AE and SAE 
All AEs occurring during the study period should be followed up according to the Good Clinical 
Practice, until the events are resolved, stabilized, or judged as no longer clinically significant, or until 
the patient is medically stable or the event is a chronic disease. Any AE assessed as study drug-related 
must be followed up until it is resolved or stabilized. 
12.1.2. Post-study AE and SAE 
The Investigator should follow up all unresolved events until the event is resolved, the patient is lost 
to follow-up, or there is another explanation for the AE. At the last scheduled visit, the Investigator 
should instruct each patient to report any subsequent events that the patient or the patient’spersonal 
physician believes to bereasonably related to participation in this study. 
Before the end of the study, the Investigator should notify the Antengene Pharmacovigilance 
Department (see Section 12.1.3.1) of any death or AE that occur at any time after a patient has 
discontinued or terminated participation in the study and that may be reasonably related to this study. 
After the end of the study, the Investigator should notify Antengene or its designee of any death or 
AE that occur at any time after a patient has discontinued or terminated participation in the study and 
that may be reasonably related to this study. If the Investigator becomes aware of the development of 
cancer or a congenital anomaly in the subequently conceied offspring of a patient who ha participated 
in this study, Antengene should also be notified. 
12.1.3. Report of Serious Adverse Events 
12.1.3.1. Reporting Requirements 
For any SAE in any patient, the Principal Investigator or designated study site personnel must report 
to the Antengene Pharmacovigilance Department (within 24 hours following initial awareness of the 
event or awareness of the follow-up information), relevant regulatory authorities, and relevant ethics 
committee. The study sites will be asked to provide the following information: 
• 
Study Protocol No 
• 
Study site and/or Investigator number 
• 
Demographic data 
• 
Brief description of the event 
• 
Date and time of onset (if applicable) 
• 
Date and time of resolution (if applicable), if the event is resolved 
• 
Current status, if the event is not resolved yet 
• 
Any concomitant therapy and medication 
• 
Investigator’s assessment on the correlation between the SAE and investigational product 
• 
Event outcome, if available 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
62/84 
 
 
All other Investigators participating in the ongoing study drug clinical study will submit the copies 
of these reports to their Institutional Review Board (IRB) Ethics Committee (EC) after receiving them, 
if applicable. According to the standard operating procedures and the policies of IRB/EC, the 
Investigator will report all the SAEs to IRB/EC. Adequate records must be kept to demonstrate that 
IRB/EC has been properly notified. 
12.2. 
Overdosage 
Overdose refers to the intentional or unintentional administration of study drug to a study patient 
using a dose level higher than that is allocated to that individual patient per the study protocol. In the 
event of drug overdose, the Investigator and Antengene should be notified immediately, and the 
patient’s AEs should be closely monitored. The patient should receive symptomatic treatment as 
appropriate, and the overdose event and related AEs and/or treatment should be recorded in the 
patient’s medical record. In addition to recording the overdose in the patient’s medical record, the 
event must be reported to the Antengene Pharmacovigilance Department using the 
Overdose/Medication Error Report Form. Any AE or SAE due to overdose observed will be handled 
as described in Section 12.2 (if applicable). 
Because ATG-010 is metabolized via GSH binding, it is predicted that hepatic GSH depletion may 
occur in the case of overdose. Therefore, in patients with abnormal liver function test, use of 
supportive measures such as SAM 400 mg by oral administration, 1-4 times/day, or other drugs that 
can replace GSH, should be considered. 
Medication errors, and administrations of study drug outside the predictable range of the study 
protocol, including drug misuse and abuse, must also be reported to the Antengene 
Pharmacovigilance Department using an Overdose/Medication Error Report Form. 
12.3. 
Pregnancy 
Pregnancy itself will not be regarded as an AE, unless it is reasonably believed that the investigational 
drug may interfere with the effectiveness of contraceptive medication. 
Each pregnancy in any patient treated with ATG-010 or patient’s partner should be reported to 
Antengene within 24 hours following the awareness of the event. The pregnancy should be followed 
up to find out the outcome, including natural or voluntary termination of pregnancy, delivery details, 
and presence or absene of any birth defects, congenital anomalities, or maternal and/or newborn 
complications. Pregnancy must be followed up and recorded, even if the patient withdraws from or 
completes the study. 
It is advised that male patients should avoid to father a chhild within 3 months from termination of 
ATG-010 treatment. There is currently no information about the effects of ATG-010 on reproductive 
capacity, pregnancy, or subsequent fetal development. 
Any pregnancy found within the period from the start of study medication to 3 months post study 
medication should be reported to the Investigator and the Sponsor. 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
63/84 
 
 
13. 
Statistical considerations 
13.1. 
Overall Considerations 
13.1.1. Statistics and Analysis Plan 
This section describes the statistical analyses to be used for evaluating the efficacy and safety 
endpoints of this trial. For the analysis details, please refer to the Statistical Analysis Plan (SAP). 
Listings of appropriate disposition, demographic, baseline, efficacy and safety parameters will be 
generated. For categorical variables, the number and percentage of patients in each parameter 
category (including the missing data category), as well as two-sided 95% confidence interval (CI) as 
appropriate, will be presented in the form of summary table. For continuous variables, the number of 
patients, mean, median, standard deviation (SD), minimum, and maximum values will be provided. 
Time to event data will be summarized by Kaplan-Meier (KM) method, using 25th, 50th (median), 
and 75th percentiles with two-sided 95% CIs, and percentage of censored observations. 
Primary analysis (including efficacy, safety, and PK evaluations) will be conducted at 3 months after 
the last patient enrollment, and supplementary efficacy and safety analysis will be conducted after 
the end of the study. 
An interim analysis will be performed when approximately 50 patients have completed the clinical 
efficacy evaluations to assess the distribution of the patients who had previously received RRMM 
treatment. During the interim analysis, the clinical efficacy in patients who had previously received 
3 classes of drugs (at least an immunomodulatory [i.e., lenalidomide], at least a protease inhibitor 
[i.e., bortezomib], and at least an anti‑CD38 antibody) should be analyzed, but the efficacy for whole 
population enrolled will not be analyzed. 
13.1.2. Sample Size Determination 
This trial is a bridging clinical study to evaluate the clinical efficacy of ATG-010 plus low‑dose 
dexamethasone in Chinese patients with relapsed/refractory MM. 
A sample size of 82 subjects with relapsed/refractory MM who have previously been treated with 
immunomodulatory agent and proteasome inhibitors (i.e., including lenalidomide and bortezomib) 
will allow for detecting a statistical significance of the target ORR of 28% against the threshold ORR 
of 15%, with power of 80% (one-sided α=0.025). 
13.1.3. Patient Disposition 
A summary of patient disposition will be provided, including the number of patients in each analysis 
population, the number of patients with unevaluable disease per IMWG criteria, the number of 
patients censored at each of PFS and OS analyses, the number of lost to follow-up patients, the 
number of patients who discontinued before completing the study, and the reasons for discontinuation. 
13.1.4. Blinding and Randomization 
This is an open-label, single-arm study, therefore blinding and randomization are not applicable. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
64/84 
 
 
13.1.5. Dose Adjustment 
Dose modifications that occured during the first treatment cycle and throughout the entire clinical 
study process will be analyzed. Meanwhile, an exploratory analysis of the effects of dose modification 
on efficacy may be performed. 
13.2. 
Analytical Dataset 
13.2.1. Analysis Population 
13.2.1.1. Modified Intent-to-treat (mITT) Population 
The modified intent-to-treat (mITT) population will include patients who received at least one dose 
of study treatment. This population will be used for efficacy analysis. 
13.2.1.2. Per Protocol Population 
The Per Protocol (PP) population will include all patients in the mITT population who meet the 
following criteria: 
• 
Have an ATG-010 compliance ≥ 70%, 
• 
Have at least 1 complete post-baseline response assessment, unless died or withdrew from study 
before that. 
• 
Have no major protocol deviation that would comprimise the efficacy evaluation. The list of 
major protocol deviations affecting statistical analysis will be finalized before database lock. 
Major protocol deviations and their impact on efficacy evaluation will be determined independent of 
knowledge of treatment response before database lock and study analyses. This population will be 
used for supportive efficacy analysis; however, if there are significant differences between the results 
of this population and those obtained in the mITT population, the efficacy evaluation will take these 
differences into account. 
13.2.1.3. Safety Population 
The safety population will include patients who have received at least one dose of study treatment. 
13.2.1.4. Subgroup Efficacy Analyses 
Subgroup comparisons of special interest will be assessed according to the Statistical Analysis Plan 
(SAP). 
13.3. 
Data Analysis and Presentation 
The disposition of patients participating in this clinical study, and the demographic and baseline 
characteristics, efficacy and safety data described in the section below will be presented in the form 
of summary tables. All relevant data collected via the eCRF and labs will be provided in the patient 
data listings. 
13.3.1. Demographic Characteristics 
The demographic characteristics of mITT, PP, and safety populations will be summarized, including 
gender, race, ethnicity, and age at the time of informed consent. For gender and race, summary 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
65/84 
 
 
statistics will include the number and percentage of patients within each category. The race category 
is a classification recorded in the database. For age at the time of informed consent, the mean, median, 
minimum, maximum, and standard deviation of each patient population will be provided. 
13.3.2. Baseline Characteristics and Medical History 
Baseline characteristics includeperformance status, duration from initial diagnosis, response to prior 
therapy, types of prior therapy, and body height/body weight. Baseline data will be tabulated using 
the summary statistics for the mITT, PP, and safety populations; formal hypothesis testing will not 
be performed. 
Baseline medical history and physical examination results for the same analysis populations will be 
presented in summary tables. 
13.3.3. Primary Endpoint 
The primary efficacy endpoint of ORR (proportion of patients who achieve PR, VGPR, CR, or sCR) 
based on mITT population and response assessment by IRC will be analyzed. For the hypothesis 
tesing of the target ORR of 28% against the threshold ORR of 15%, a two-sided 95% confidential 
interval of the ORR will be provided. A lower bound of this interval >15% will indicate statistical 
significance of the test. ORR will also be analyzed based on the response assessments made by 
Investigator. 
13.3.4. Secondary Endpoints 
The following secondary efficacy endpoints for the mITT and PP populations will be analyzed 
separately. 
• 
Survival rate (SR) at 6, 9, and 12 months 
• 
Duration of response (DOR) = Duration from the first observation of at least partial response 
(PR) to time of disease progression (PD] or death due to PD, whichever comes first. DOR for 
death due to any reasons other than PD will be censored. 
• 
Clinical benefit rate (CBR) = CBR+minimal response [MR], and duration of clinical benefit 
(duration from the first observation of at least MR to PD or death due to PD, whichever comes 
first). Duration of clinical benefit for death due to any reasons other than PD will be censored.  
• 
Disease control rate (DCR) = CBR+stable disease [SD; for at least 12 weeks]) 
• 
Progression-free survival (PFS) = Duration from start of study treatment to PD or death 
[irrespective of cause of death], whichever comes first) 
• 
Time to progression (TTP) = Duration from start of study treatment to time of PD 
• 
Overall survival (OS) = Duration from start of study treatment to death 
The Kaplan-Meier (KM) method will be used to analyze the time to event endpoints (including 
duration of response, PFS, TTP, and OS), including the median estimate, 25th and 75th percentiles, 
and two-sided 95% CIs. The CBR and DCR will be summarized using two-sided 95% confidence 
intervals. 
In addition, the following secondary endpoints of safety and tolerability will be analyzed using the 
Safety Analysis Set. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
66/84 
 
 
• 
Safety and tolerability will be analyzed per National Cancer Institute (NCI)-Common 
Terminology Criteria for Adverse Events (CTCAE) v 4.03. 
• 
The ATG-010 PK profile of this patient population will be described. 
• 
Cytogenetic and fluorescence in situ hybridization (FISH) prognostic markers, including 
chromosomal aberrations [e.g., del17p, t(4;14), t(14;16), del13] and other cytogenetic categories 
of MM. 
13.3.5. Pharmacokinetic 
Plasma analysis will be performed using validated High-Performance Liquid 
Chromatography-Tandem Mass Spectrometry (HPLC/MS-MS) to determine the blood 
concentration of ATG-010. The drug concentrations will be used to plot tables and graphs for each 
subject’s drug concentration-time data and average drug concentration-time data. The following 
PK parameters of ATG-010 will be obtained by analyzing effective blood drug concentration data:  
• Maximum drug concentration (Cmax, observed value)  
• Time to maximum drug concentration (Tmax, observed value)  
• Areas under the drug concentration-time curve from time 0 to the last measurable 
concentration and to infinity (AUC0-last and AUC0-∞, respectively) 
• Terminal elimination half-life (T½)  
• Plasma clearance (CL)  
• Volume of distribution (Varea) 
13.3.6. Safety Data 
Safety analysis will be performed on the total patient population receiving any dose of study treatment, 
and the results will be listed. Each patient’s original dose level will be used for safety analysis; in the 
primary safety analysis, dose escalation or reduction will not be independently classified. An 
additional exploratory assessment of the effects of dose modification on safety may be performed. 
13.3.6.1. Adverse Event 
AEs will be coded per Medical Dictionary for Regulatory Activities (MedDRA) and presented in 
tables and listings per MedDRA System Organ Class (SOC) and Preferred Term (PT). 
Events deemed to be treatment-emergent will be included in AE analysis, where “treatment-emergent” 
refers to any AE or exacerbation of a pre-existing disease that emergesonor after the first dose of 
study treatment or within 30 days after last dose of study treatment, or any event that emerges prior 
to the end of study and is considered drug-related by the Investigator. AEs with partial dates available 
will be assessed using the existing date information to determine if they are treatment-emergent; AEs 
with dates completely missing will be assumed as treatment-emergent. No formal hypothesis testing 
will be performed on the incidence rates of AEs. 
AEs will be summarized per patients’ incidence rates; therefore, each patient will be counted only 
once for a given AE (Preferred Term) in any listing. The number and percentage of patients with any 
treatment-emergent adverse event (TEAE) will be summarized per treatment group, and stratified per 
SOC and Preferred Term. The number and percentage of patients with TEAE that is assessed as at 
least possibly related to treatment by the Investigator will also be listed. The number and percentage 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
67/84 
 
 
of patients with any Grade ≥3 TEAE will be listed in the same way. 
The Investigator will assess the causal relationship between an AE and the study drug as not related 
or related. If a patient experiences the same AE repeatedly, events with the highest severity and/or 
with a strong causal relationship with treatment will be used for the purpose of tabulations. 
All SAEs reported will be listed.  
All AEs (emerging during and after treatment) will be presented in the individual patient data listings 
and will be classified per treatment, patient, and study day. In addition, individual patient listings will 
be provided for the following events: deaths, SAEs, and AEs leading to withdrawal. 
13.3.6.2. Laboratory Data 
Clinical laboratory test values will be presented using traditional units of International System of 
Units (SI). For various clinical laboratory parameters (including hematology, clinical chemistry, 
coagulation, and urinalysis), the actual value and change from baseline (Day 1, prior to first dose of 
study drug) to each on-study assessment will be summarized. In the presence of duplicate values, the 
last non-missing value of each study date/time will be used. If Day 1 data of a pre-defined 
patient/parameter are not available, the baseline values will be replaced with the screening values. 
Severity of selected clinical laboratory measures (e.g., measures with corresponding CTCAE grading) 
will be determined per CTCAE v4.03 criteria. Laboratory values at CTCAE Grade ≥3 will be 
presented in data listings. Shift tables will be generated to list the changes from baseline to worst on-
study value and from baseline to last on-study value relative to CTCAE classification. 
13.3.6.3. Vital Signs, Physical Examination and ECOG Performance Status  
For vital signs, the actual value and change from baseline (Day 1) to each study assessment will be 
summarized. Shift tables will be generated to list the changes from baseline to worst on-study value 
and to last on-study ECG performance status. The individual patient listing of all vital sign 
measurements and ECOG performance status scores will be presented in data listings. 
The physical examination results at Screening and changes in the physical examination results during 
the study will be summarized. All physical examination results will be presented in the individual 
patient data listings. 
13.3.6.4. ECG Results 
ECG results, including heart rate and PR, QRS, QT, and QTc (calculated by Fridericia’s correction 
formula) intervals, will be summarized in a descriptive manner. If Bazett’s correction formula is 
already entered by the study site, Fridericia-corrected QTc interval (QTcF) will be deduced using the 
following formula: QT/(RR^[1/3]), where, RR=60/heart rate. Actual values and changes from 
baseline will be reported at each study visit. 
Each patient’s ECG data will be provided in a data listing. 
13.3.6.5. Concomitant meds 
Concomitant medications used will be included in the individual patient data listings. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
68/84 
 
 
13.3.7. Missing Data Handling Procedures 
The missing data handling procedures will be performed following the SAP. 
13.4. 
Changes in Study Conduct or Planned Analyses 
All deviations from the original statistical analysis plan will be recorded and presented in the final 
clinical study report. 
 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
69/84 
 
 
14. 
Regulatory Considerations 
14.1. 
International Conference on Harmonization – Good Clinical Practices 
The study conduct, assessment and recording procedures defined in this study protocol are designed 
to ensure the study is conducted by Antengene, authorized representatives, and Investigators in 
compliance with the Good Clinical Practice (GCP) in the International Council for Harmonisation of 
Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines E6 and the general 
ethical principles in the Declaration of Helsinki. The study will be implemented after approval by 
IRB/EC. Investigator will implement all aspects of this study in accordance with the applicable laws 
of the country or region in which related regulatory authorities are located. 
14.2. 
Investigator’s Responsibilities 
Investigator’s responsibilities are stipulated in ICH GCP guidelines and local laws and regulations. 
Antengene staff or authorized representatives will assess and approve Investigators, while 
investigators will be responsible for choosing the study personnel. 
Investigators should ensure that all personnel assisting in the study work have a full understanding of 
the study protocol, amendments, study treatment, and study-related responsibilities and functions. 
Investigators should be responsible for keeping the list of other qualified personnel assisting 
Investigators and delegated with important study-related responsibilities. 
Investigators are responsible for keeping the records of all subjects who have signed informed consent 
forms (ICF) and accepted for study screening. For screen-failure subjects, the reason must be recorded 
in their source documents. 
Investigators or designated personnel must be present during the monitoring period to check data, 
solve queries, and facilitate direct access to view subjects’ records (e.g., medical records, outpatient 
medical records, inpatient medical records, and study-related medical records) as to complete the 
source data verification. Investigators must ensure CRFs are filled and the queries are resolved in a 
timely andaccurate CRF manner. 
14.3. 
Subject Information and Informed Consent 
Investigator must obtain the informed consent of legal representative before performing any 
study-related procedures. 
The record of informed consent performed before the study subject enters the study and the process 
of obtaining informed consent should be kept in the subject's source documents, including relevant 
dates. The original copy of ICF signed and dated by the study subject and the personnel explaining 
the ICF before the subject enters the study must be kept in the Investigator's study file, with a copy 
provided to the subject. In addition, if the study protocol is amended and the amendment has an impact 
on the content of informed consent, the ICF must be modified accordingly. After the study protocol 
is amended, subjects participating in the study must agree to sign the modified ICF. The original copy 
of modified ICF signed and dated by the study subject and the personnel explaining the ICF must be 
kept in the Investigator's study file, with a copy provided to the subject. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
70/84 
 
 
14.4. 
Confidential 
Antengene confirm that subjects have the right to prevent privacy violations and will follow the 
requirements of ICH and other local regulations (whichever is the strictest). Antengene requests 
Investigators to allow the representatives of Antengene and if necessary, representatives of regulatory 
authorities to inspect and/or copy any study-related medical records according to local laws. 
Direct access to medical records should be exempted or authorized outside the ICF signed by subjects, 
and Investigator is responsible for obtaining such a written permission from appropriate individuals. 
14.5. 
Protocol Amendment 
Any amendment of this study protocol must be approved by Antengene Clinical Study 
Physician/Medical Monitor. An amendment will be submitted to IRB/EC for written approval. A 
written approval must be obtained before the amended study protocol is implemented. The 
Investigator’s name, study protocol number, study title, and amendment number (if applicable) should 
be detailed in the signed written approval letter from IRB/EC. Administratively, an amendment 
involving logics only does not require approval from IRB/IEC, but should be submitted to IRB/EC 
for information purpose. 
14.6. 
Institutional Review Board/Independent Ethics Committee Review and Approval 
Prior to the start of the study , the study protocol, ICF, and any other appropriate documents will be 
submitted to IRB/EC, and a cover letter or form will be attached simultaneously to list the submitted 
documents, their issue dates, and study sites (or jurisdictional area or region, depending on the 
situation) to be approved. Where appropriate, the documents will also be submitted to regulatory 
authorities according to local laws. 
Antengene or authorized representative shall not provide Investigators with IP until all the ethical and 
legal documents required for study initiation are received. These documents must contain a list of 
IRB/EC members and their occupation and qualification. IRB/EC shall not disclose the name, 
occupation or qualification information of IRB/EC committee members, and they should issue a 
statement to certify that the composition of IRB/EC complies with GCP requirements. For example, 
this list can be replaced with the IRB General Guarantee Numbers. 
The study protocol title, number, amendment number (if applicable), study sites (or jurisdictional area 
or region, , depending on the situation), and other documents reviewed should be mentioned in the 
official approval letter from IRB/EC. The approval letter must indicate the date the decision is made 
and must be officially signed by the committee members of IRB/EC. All ethical and legal 
requirements must be met before the first subject is enrolled in the study. 
All subsequent study protocol amendments must be notified to IRB/EC and regulatory authorities (if 
applicable) according to local laws. Any amendment must be assessed to determine whether an 
official approval is required and whether the ICF should be amended accordingly. 
Investigators must properly keep all records of communication with IRB/EC and all records of 
communication between coordinating Investigators and IRB/EC. This requirement also applies to any 
communication between Investigators (or coordinating Investigators, if applicable) and regulatory 
authorities. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
71/84 
 
 
14.7. 
Continuously Providing Information to Institutional Review Board/Independent 
Ethics Committee 
If requested by law or IRB/EC, Investigator must submit the following information to IRB/EC: 
• 
Provide the information of serious or unexpected AE as soon as possible; 
• 
Periodic report on study progress; 
• 
Study protocol deviations or any situation that may involve increased subject risks. 
14.8. 
End of Study 
Antengene reserves the right to terminate this study at any time for reasonable medical or 
administrative reasons. Any premature termination of study will be properly recorded according to 
local requirements (e.g., IRB/EC, regulatory authorities, etc.). 
In addition, Investigator or Antengene has the right to terminate a study site from participating in the 
study work at any time during the study period for medical or administrative reasons, for example: 
• 
Unsatisfied subject enrollment; 
• 
Non-compliance with GCP requirements; 
• 
Inaccurate or incomplete collection on data; 
• 
Falsified records; 
• 
Non-compliance with requirements of study protocol. 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
72/84 
 
 
15. 
Data Processing and Records Keeping 
15.1. 
Data/Documents 
Investigators must ensure that records and documents related to study conduct and study drug 
dispensing are complete, accurate, archived, and properly kept. Examples of source documents 
include: hospital records; clinic and outpatient medical records; laboratory test sheets; memos; subject 
diaries or assessment lists; dispensing records; recorded data from automatic instrument; certified 
photocopies or transcripts; microfilms; X-ray film results and reports; records kept by pharmacy and 
laboratory, and CRF copies or CD-ROMs. 
15.2. 
Data Management 
In this clinical trial, data will be collected through CRF and will be entered into the clinical database 
according to the standard operating procedures (SOP) of Antengene or authorized representative. 
These data will be electronically verified using the programed edit check method specified by the 
clinical team. Any data discrepancies identified will be notified to the clinical team and if necessary, 
study site personnel. The database will be modified accordingly after these problems are solved. All 
changes to the data will be tracked through internal audit trail system. 
15.3. 
Study-related Records Keeping 
Essential documents will be kept by Investigators for at least 2 years after the marketing application 
of the ICH region is eventually approved, or there is no more pending or expected marketing 
authorization in the ICH region, or at least 2 years after the clinical development of the IP is officially 
discontinued. Investigators must keep these documents according to the time requirement described 
above or per local laws or (whichever is longer). Essential documents include but are not limited to: 
• 
ICFs signed by all subjects; 
• 
A list of subject identification codes, screening record form (if applicable), and enrollment 
record form; 
• 
All communication records between the Investigator and IRB/EC; 
• 
A list of IRB/EC members; 
• 
All communication records of between the Investigator and Antengene and its authorized 
representative; 
• Lists of other qualified personnel assisting the investigator, and delegates with important 
study-related responsibilities by Investigator, and their responsibilities in the study, 
curriculum vitae, and signature; 
• 
Copies of a CRF (e.g., paper version) and modification records of all subjects; 
• 
IP accountability records; 
• 
Records of any body fluid or tissue sample; 
• 
All other source documents (subject records, hospital records, laboratory test records, etc.); 
• 
All other documents listed in Section 8 of ICH GCP Consensus Guideline (Essential 
Document for Conduct of a Clinical Trial). 
If the Investigator wishes to assign essential documents to others for storage, transfer the documents 
to other place, or is not able to preserve keep the documents within a specific period of time, 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
73/84 
 
 
Antengene must be notified. Investigator must obtain a written approval from Antengene before 
destroying any record. If the Investigator is not able to fulfill this obligation, he/she must apply for 
Antengene's permission to arrange a replacement. Details about this arrangement should be recorded. 
If the relevant health department requests to access the study documents, all documents requested 
should be provided. Investigators/hospitasl should take action to prevent accidental or premature 
destroying of these documents. 
15.4. 
Information Disclosure 
All information provided to Investigators by Antengene or its designee will be kept strictly 
confidential. No disclosure is allowed unless it is compliant with the release right granted to the 
Investigator in the clinical trial agreement. 
No information about the study or its progress will be disclosed to any personnel not participating in 
this study other than Antengene or its authorized representative, or be kept confidential to IRB or 
similar committees, unless required by law. 
15.5. 
Reporting and Release of Study Documents 
Antengene will publish the results of this study in peer-reviewed medical publications or journals, 
and may also use the study findings for educational purposes. In addition, Antengene may submit this 
study and its results upon the request of the local health department to include this study in all 
appropriate health department’s reserch registries, and may publish this study on theresearch registry 
website of the health department. Antengene will choose the first author based on several 
considerations, including but not limited to the study participation, subject enrollment, contribution 
to study protocol formulation and, analysis, writing of manuscript, relevant abstracts, and 
performance in the study. 
 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
74/84 
 
 
16. 
Quality Control and Quality Assurance 
Antengene or authorized representative will carefully monitor all aspects of the study to ensure 
compliance with applicable government regulations and current GCP, standard operating procedures. 
16.1. 
Study Monitoring and Source Data Verification 
Antengene ensures that appropriate monitoring procedures will be adopted before, during, and after 
study conduct. Review all aspects of the study with the Investigator and study personnel during the 
study initiation visit and/or Investigator meetings. Antengene representative will review the study 
protocol, CRF, informed consent process, records storage, and AE/SAE reporting, and other aspects 
with the Investigator before subject enrollment. Monitoring includes study site visits, and any proper 
communications by mail, e-mail, fax or phone with the Investigator and study personnel. During the 
monitoring visit, Antengene representative will check/inspect the facility, study drug storage area, 
CRF, subject source documents, and all other study documents according to the study monitoring 
plan. 
The accuracy of data will be checked during source data verification, i.e., directly comparing the data 
recorded in the CRF with appropriate source documents. Any discrapancies identified will be checked 
by the Investigator and/or study personnel. For any necessary modification, a query will be generated 
directly in the CRF to the Investigator and/or study personnel. The informed consent, compliance 
with inclusion/exclusion criteria, as well as SAE documents and appropriate records will be verified 
according to the monitoring procedures. Other monitoring may also be required in a specialized study 
monitoring plan. 
16.2. 
Auditing and Inspection 
In addition to routine monitoring procedures, Antengene also has an internal GCP quality assurance 
team. The representative of this team will audit clinical study activities according to the SOP of 
Antengene or its authorized representative to assessstudy compliance per GCP and regulations. 
Investigators are requested to permit IRB/IEC, regulatory authorities (e.g., National Medical Products 
Administration of China), and company's authorized representatives to have direct access to study 
conducting facilities, source documents, CRF, and applicable supporting records of subject 
participation, so that auditing and inspection can be carried out. Investigators should always be 
present during auditing and/or inspection. Whenever a regulatory authority contacts an Investigator 
and requests an inspection, the Investigator should notify Antengene immediately. 
 
 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
75/84 
 
 
17. 
References 
1. 
ACS (American Cancer Society). Key statistics for multiple myeloma. Available on line at 
http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-key- 
statistics.Accessed 03Aug2016. 
2. 
Altura RA, Olshefski RS, Jiang Y, Boué DR.  Nuclear expression of survivin in paediatric 
ependymomas and choroid plexus tumours correlates with morphologic tumour grade. Brit J 
Cancer.2003;89(9):1743–1749. 
3. 
Azmi AS, Al-Katib A, Aboukameel A, et al. Selective inhibitors of nuclear export for the 
treatment of non-Hodgkin’s lymphomas. Haematol.2013;98(7):1098-1106. 
4. 
Bazett HC. An analysis of the time-relations of electrocardiograms.Heart 1920;7:353 70. 
5. 
Brown CJ, Dastidar SG, Quah ST, et al. C-terminal substitution of MDM2 interacting peptides 
modulates binding affinity by distinctive mechanisms. PLoS One.2011;6(8):e24122. 
6. 
Chen C, et al. Anti-Tumor Activity of SELINEXOR (KPT-330), an Oral Selective Inhibitor of 
Nuclear Export (SINE), ± Dexamethasone in Multiple Myeloma Preclinical Models and 
Translation in Patients with Multiple Myeloma.2014 EHA Annual Meeting, June 12 - June 15, 
2014, Milan, Italy. 
7. 
Chen CI, Gutierrez M, Siegel DS, et al. Selinexor demonstrates marked synergy with 
dexamethasone (Sel-Dex) in pre-clinical models and in patients with heavily pretreated 
refractory multiple myeloma.2014 ASH Annual Meeting, December 06 – 09, 2014, San 
Francisco. 
8. 
Chesi M, Matthews GM, Garbitt VM, et al. Dose response in a genetically engineered mouse 
model of multiple myeloma is predictive of clinical efficacy. Blood 2012 (July 12); 120(2):376-
385. 
9. 
Culjkovic B, Topisirovic I, Skrabanek L, et al. elF4E is a central node of an RNA regulon that 
governs cellular proliferation. J Cell Biol 2006;175:415-426. 
10. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight 
be known. Arch Intern Medicine.1916;17:863-871. 
11. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple 
myeloma. Leukemia 2006;20(9):1467-73. 
12. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying 
cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. 
Blood.2007;1;109(3):874-85. 
13. Fragomeni RAS, Chung HW, Landesman Y, et al. CRM1 and BRAF inhibition synergize and 
induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther.2013;12(7):1171-9. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
76/84 
 
 
14. Fridericia L. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei 
Herzkranken. [The duration of systole in the electrocardiogram of normal subjects and of 
patients with heart disease]. Acta Medica Scandinavica.1920;53:469-86. 
15. Gao J, Azmi AS, Aboukameel A, Kauffman M, Shacham S, Abou-Samra AB, Mohammad RM. 
Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation 
in pancreatic cancer. Oncotarget.2014 15;5(11):3444-54. 
16. Gray LJ, Bjelogrlic P, Appleyard VC, et al. Selective induction of apoptosis by leptomycin B in 
keratinocytes expressing HPV oncogenes. Int J Cancer.2007:120(11):2317-2324. 
17. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J 
Clin Oncol.2005;23:3412-3420. 
18. International Myeloma Working Group.Criteria for the classification of monoclonal 
gammopathies, multiple myeloma and related disorders: a report of the International Myeloma 
Working Group. Br J Haematol.2003;121:749-757. 
19. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-
kappaB pathway in multiple myeloma. Cancer Cell.2007 Aug;12(2):131-44. 
20. Koehler A, Hurt E. Exporting RNA from the nucleus to the cytoplasm. Nat Rev Mol Cell 
Biol.2007;8:761-73. 
21. Kojima K, Kornblau SM, Ruvolo V, et al. Prognostic impact and targeting of CRM1 in acute 
myeloid leukemia. Blood.2013;121(20):4166–4174. 
22. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple 
myeloma: 
changes 
in 
early 
mortality 
and 
outcomes 
in 
older 
patients. 
Leukemia.2014;28(5):1122-8. 
23. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus 
criteria for response and minimal residual disease assessment in multiple myeloma. Lancet 
Oncol.2016;17:e328-46. 
24. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med.2004;351:1860-1873. 
25. Lain S, Xirodimas D, Lane DP. Accumulating active p53 in the nucleus by inhibition of nuclear 
export: a novel strategy to promote the p53 tumor suppressor function. Exp Cell 
Res.1999;253(2):315-324. 
26. Lapalombella R, Sun Q, Williams K, et al. Selective inhibitors of nuclear export show that 
CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood.2012;120(23):4621-4634. 
27. Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: 
implications for targeted therapy. Cancer Cell.2014 Jan 13;25(1):91-101. 
28. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987; 317:1098. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
77/84 
 
 
29. Mutka SC, Yang WQ, Dong SD, et al. Identification of nuclear export inhibitors with potent 
anticancer activity in vivo. Cancer Res.2009;69(2):510-517. 
30. National Cancer Institute.Cancer Therapy Evaluation Program [CTEP] Policy and Guidelines 
for Accountability and Storage of Investigational Agents, available on line at 
http://ctep.cancer.gov/protocolDevelopment. 
31. National Cancer Institute.Cancer Therapy Evaluation Program [CTEP] Common Terminology 
Criteria 
for 
Adverse 
Events 
(CTCAE) 
version 
4.03. 
Available 
on 
line 
at 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf 
32. National Comprehensive Cancer Network®.NCCN Clinical Practice Guidelines in Oncology 
(NCCN CPGO). Available at http://www.nccn.org/professionals. 
33. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer.1996;74(4):648-
649. 
34. Optometric Clinical Practice Guideline: Care of the Adult Patient with Cataracts (CPG8). 
American Optometric Association at www.aoa.org. 
35. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group.Am J Clin Oncol.1982;5:649-655. 
36. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 
2009;374:324-339. 
37. Rajkumar SV, Harousseau JL, Durie B, et al, for the International Myeloma Workshop 
Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: 
report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117:4691-95. 
38. Ranganathan P, Yu X, Na C, et al. Preclinical activity of a novel CRM1 inhibitor in acute 
myeloid leukemia. Blood.2012;120(9):1765–1773. 
39. Roberts BJ, Hamelehle KL, Sebolt JS, Leopold WR. In vivo and in vitro anticancer activity of 
the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). 
Cancer Chemother Pharmacol.1986;16(2):95-101. 
40. Schmidt J, Braggio E, Kortuem KM, et al. Genome-wide studies in multiple myeloma identify 
XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-
276.Leukemia.2013;27(12):2357-65. 
41. Selinexor/KPT-330 Investigator’s Brochure, 2019. 
42. Senapedis WT, Baloglu E, Landesman Y. Clinical translation of nuclear export inhibitors in 
cancer. Semin Cancer Biol.2014 Aug;27C:74-86. 
43. Sharpless NE, DePinho RA. Gone but not forgotten. Nature.2007;445(7128):606-7. 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
78/84 
 
 
44. Tai Y-T, Landesman Y, Acharya C, Calle Y, et al. CRM1 inhibition induces tumor cell 
cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and 
therapeutic implications. Leukemia.2014;28:155-165. 
45. Tan DS, Bedard PL, Kuruvilla J, Siu LL, Razak AR. Promising SINEs for embargoing nuclear-
cytoplasmic export as an anticancer strategy. Cancer Discovery.2014 May;4(5):527-37. 
46. Tiedemann RE, Zhu YX, Schmidt J, et al. Identification of molecular vulnerabilities in human 
multiple myeloma cells by RNA interference lethality screening of the druggable genome. 
Cancer Res.2012 Feb 1;72(3):757-68. 
47. Turner JG, Sullivan DM. CRM1-mediated nuclear export of proteins and drug resistance in 
cancer. Curr Med Chem.2008;15(26):2648-55. 
48. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. 
Biochem Pharmacol.2012;83(8):1021-1032. 
49. Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, 
Sullivan DM. CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to 
Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo.J Cancer.2013 Sep 
10;4(8):614-25. 
50. Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-dependent nuclear 
export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol.2014 
Aug;27C:62-73. 
51. Van der Watt PJ, Maske CP, Hendricks DT, et al. The Karyopherin proteins, Crm1 and 
Karyopherin beta1, are overexpressed in cervical cancer and are critical for cell survival and 
proliferation. Int J Cancer.2009;124(8):1829-1840. 
52. Vogl DT, Dingli D, Cornell RF, et al. Selinexor and low dose dexamethasone (Sd) in patients 
with lenalidomide, pomalidomide, bortezomib, carfilzomib and anti-CD38 Ab refractory 
multiple myeloma (MM): STORM Study.Blood.2016; 128, 491-491. 
53. Walker CJ, Oaks JJ, Santhanam R, et al. Preclinical and clinical efficacy of XPO1/CRM1 
inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood.2013;22(17):3034–
3044. 
54. Xu D, Farmer A, Chook YM. Recognition of nuclear targeting signals by Karyopherin- beta 
proteins.Curr Opin Struct Biol.2010;20(6):782-790. 
55. Yang J, Bill MA, Young GS, La Perle K, Landesman Y, Shacham S, Kauffman M, Senapedis 
W, Kashyap T, Saint-Martin JR, Kendra K, Lesinski GB. Novel Small Molecule XPO1/CRM1 
Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in 
Human Melanoma Cells.PLoS One.2014 Jul 24;9(7):e102983. 
 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
79/84 
 
 
Appendix 1. Eastern Cooperative Oncology Group (ECOG) Performance Status Criteria 
Table 8:  Eastern Cooperative Oncology Group (ECOG) Performance Status Criteria 
ECOG performance status score 
Grade 
Description 
0 
Normal activity. Fully active, able to carry on all pre-disease performance without restriction. 
1 
Symptoms, but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to 
carry out work of a light or sedentary nature (e.g., light housework, office work). 
2 
Time in bed <50%. Ambulatory and capable of all self-care, but unable to carry out any work 
activities. Up and about >50% of waking hours 
3 
Time in bed >50%. Capable of only limited self-care; confined to bed or chair more than 50% of 
waking hours. 
4 
100% bedridden. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
5 
Dead 
Origin: Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative 
Oncology Group.Am J Clin Oncol.1982;5:649-655) 
 
Appendix 2. International Staging System for MM 
Table 9:  International Staging System for MM 
Phase 
Characteristics 
Stage I 
β2-microglobulin <3.5 mg/L, albumin ≥3.5 g/dL 
Stage II 
β2-microglobulin <3.5 mg/Land albumin <3.5 g/dL, or β2-microglobulin 3.5-5.5 mg/L 
irrespective of the serum albumin 
Stage III 
β2-microglobulin ≥5.5 mg/L 
Origin: Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin 
Oncol.2005;23:3412-3420 
 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
80/84 
 
 
Appendix 3. International Myeloma Working Group Response Criteria, Myeloma 
Table 10:  International Myeloma Working Group Response Criteria (Kumar 2016) 
Standard IMWG Response Criteria1, 2, 3 
Response subcategory 
Response criteria 
Complete Response (CR) 
Negative IFE of serum and urine, disappearance of any soft tissue 
plasmacytomas (SPD), and <5% plasma cells in bone marrow aspirates 
Stringent Complete Response 
(sCR) 
CR as defined above plus normal FLC ratio 4 and absence of clonal cells in 
bone marrow biopsy by immunohistochemistry (κ/λ ratio ≤ 4:1 or ≥ 1:2 for κ 
and λ patients, respectively, after counting ≥ 100 plasma cells 5) 
Very Good Partial Response 
(VGPR) 
Serum and urine M-protein detectable by IFE but not on electrophoresis, or 
≥90% reduction in serum M-protein plus urine M-protein level <100 mg per 24 
hours 
Partial Response (PR) 
≥50% reduction of serum M-protein plus reduction in 24-hour urine M-protein 
by ≥90% or to <200 mg per 24 hours. 
If the serum and urine M-protein are unmeasurable, a ≥50% decrease in the 
difference between involved and uninvolved FLC levels is required in place of 
the M-protein criteria. 
If serum and urine M-protein are unmeasurable, and serum FLCs are also 
unmeasurable, ≥50% reduction in plasma cells is required in place of M-
protein, provided baseline bone marrow plasma cell percentage was ≥30%. 
In addition to the above criteria, if present at baseline, a ≥50% reduction in the 
size (SPD) of soft tissue plasmacytomas is also required 6 
Minimal Response (MR) 
≥25% but <49% reduction of serum M-protein, and reduction in 24-h urine M-
protein by 50-89%. 
In addition to the above criteria, if present at baseline, a ≥50% reduction in the 
size (SPD) of soft tissue plasmacytomas is also required 6 
Stable Disease (SD) 
Not recommended for use as an indicator of response; stability of disease is 
best described by providing the TTP estimates. Not meeting criteria for CR, 
VGPR, PR or progressive disease 
Progressive of Disease (PD) 7,8 
Any one or more of the following criteria: 
Increase of 25% from lowest confirmed response value in any one or more of 
the following criteria. 
Serum M-protein with an absolute increase ≥ 0.5 g/dL; 
Serum M-protein increase ≥1 g/dL, if the lowest M component was ≥5 g/dL 
Urine M-protein (absolute increase must be ≥200 mg/24 hr); 
In patients without measurable serum and urine M-protein levels, the 
difference between involved and uninvolved FLC levels (absolute increase 
must be >10 mg/dL); 
In patients without measurable serum and urine M-protein levels and without 
measurable FLC levels, bone marrow plasma cell percentage irrespective of 
baseline status (absolute increase must be >10%); 
Appearance of new lesions, ≥50% increase from nadir in SPD 6 of >1 lesion, or 
a ≥50% increase in the longest diameter of a previous lesion >1 cm in short 
axis; 
≥50% increase in circulating plasma cells (minimum of 200 cells per µL) if this 
is the only measure of disease 
Clinical relapse 
Clinical relapse requires one or more of the following criteria: 
Direct indicators of increasing disease and/or end organ dysfunction (CRAB 
features) related to the underlying clonal plasma-cell proliferative disorder. It is 
not used in calculation of TTP or PFS but is listed as something that can be 
reported optionally or for use in clinical practice; 
Development of new soft tissue plasmacytomas or bone lesions (osteoporotic 
fractures do not constitute progression); 
Definite increase in the size of existing plasmacytomas or bone lesions. A 
definite increase is defined as a 50% (and ≥1 cm) increase as measured serially 
by the SPD6 of the measurable lesion. 
Hypercalcemia (>11 mg/dL); 
Decrease in hemoglobin of ≥2 g/dL not related to therapy or other non-

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
81/84 
 
 
myeloma-related conditions; 
Rise in serum creatinine by 2 mg/dL or more from the start of the therapy and 
attributable to myeloma. 
Hyperviscosity related to serum paraprotein 
Relapse from CR (to be used only 
if the endpoint is disease-free 
survival) 
Any one or more of the following criteria: 
Reappearance of serum or urine M-protein by immunofixation or 
electrophoresis; 
Development of ≥5% plasma cells in the bone marrow; 
Appearance of any other sign of progression (i.e., new plasmacytoma, lytic 
bone lesion, or hypercalcemia see above) 
Relapse from MRD Negative (to 
be used only if the endpoint is 
disease-free survival) 
Any one or more of the following criteria: 
Loss of MRD negative state (evidence of clonal plasma cells on NGF or NGS, 
or positive imaging study for recurrence of myeloma); 
Reappearance of serum or urine M-protein by immunofixation or 
electrophoresis; 
Development of ≥5% clonal plasma cells in the bone marrow; 
Appearance of any other sign of progression (i.e., new plasmacytoma, lytic 
bone lesion, or hypercalcemia) 
Abbreviations: ASCT = autologous stem cell transplantation; CR = complete response; CRAB features: calcium 
elevation, kidney failure, anemia, lytic bone lesion; CT = computed tomography; DOR = duration of response; FDG 
= fluorodeoxyglucose; FLC = free light chain; hr = hour; Ig = immunoglobulin; IMWG = International Myeloma 
Working Group; MM = multiple myeloma; MR = minimal response; MRD = minimal residual disease; MRI = 
magnetic resonance imaging; NGF = next-generation flow cytometry; NGS = next-generation sequencing; PD = 
progressive disease; PET = positron emission tomography; PFS = progression-free survival; PR = partial response; 
sCR = stringent complete response; SD = stable disease; SPD = sum of products of two longest perpendicular 
diameters; TTP = time to progression; VGPR = very good partial response. 
Source: Kumar, 2016 
 
1 All response categories require two consecutive assessments made at any time before the institution of any new therapy; 
for MRD there is no need for two consecutive assessments, but information on MRD after each treatment stage is 
recommended (e.g., after induction therapy, high-dose therapy/ASCT, consolidation, maintenance). MRD tests should 
be initiated only at the time of suspected CR. All categories of response and MRD require no known evidence of 
progressive or new bone lesions if radiographic studies were performed. However, radiographic studies are not required 
to satisfy these response requirements except for the requirement of FDG-PET if imaging MRD-negative status is 
reported. 
2 According to IMWG, the quantitative Ig level measured by turbidimetry can be used to replace SPEP in determining 
the conventional M-protein measure of patients with IgA or IgD myeloma. In addition, according to IMWG, response 
can be confirmed if the patient fails to provide 24-h urine sample collection after the screening activities. See the section 
“Practical considerations for application of IMWG consensus criteria” in the guidelines (Page e340; Kumar, 2016) 
3 Derived from international uniform response criteria for MM. (Durie 2011). MR definition and clarifications derived 
from Rajkumar (Rajkumar 2011). When the only method to measure disease is by serum FLC levels: complete response 
can be defined as a normal FLC ratio of 0.26 to 1.65 in addition to the CR criteria listed previously. VGPR in such 
patients requires a ≥90% decrease in the difference between involved and uninvolved FLC levels. All response 
categories require two consecutive assessments made at any time before the institution of any new therapy; all 
categories also require no known evidence of progressive or new bone lesions or extramedullary plasmacytomas if 
radiographic studies were performed. Radiographic studies are not required to satisfy these response criteria. Bone 
marrow assessments do not need to be confirmed. Each category, except for SD, will be considered unconfirmed until 
the confirmatory test is performed. The date of the initial test is considered as the date of response for evaluation of 
time dependent outcomes such as DOR. 
4 All recommendations regarding clinical uses relating to serum FLC levels or FLC ratio are based on results obtained 
with the validated Freelite test (Binding Site, Birmingham, UK). 
5 Presence/absence of clonal cells on immunohistochemistry is based upon the κ/λ/L ratio. An abnormal κ/λ ratio by 
immunohistochemistry requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting presence of 
an abnormal clone is κ/λ of >4:1 or <1:2. 
6 Plasmacytoma measurements should be taken from the CT portion of the PET/CT, or MRI scans, or dedicated CT scans 
where applicable. For patients with only skin involvement, skin lesions should be measured with a ruler. Measurement 
of tumor size will be determined by the SPD. 
7 Positive immunofixation alone in a patient previously classified as achieving a complete response will not be 
considered progression. For purposes of calculating time to progression and PFS, patients who have achieved a CR and 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
82/84 
 
 
are MRD-negative should be evaluated using criteria listed for progressive disease. Criteria for relapse from a CR or 
relapse from MRD should be used only when calculating disease-free survival. 
8 In the case where a value is felt to be a spurious result per Investigator’s discretion (e.g., a possible laboratory error), 
that value will not be considered when determining the lowest value. 
 
For questions about the interpretation of these criteria, please refer to the section “Practical considerations for 
application of IMWG consensus criteria” of the guidelines. 
(Page e340, Kumar 2016). 
 
 
 

ATG-010-MM-001 
 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
83/84 
 
 
Appendix 4. ATG-010 (SELINEXOR) Preparation and Administration 
Description of ATG-010 
ATG-010 is a selective inhibitor of nuclear export (SINE) ATG-010 blocks nuclear export 
specifically by binding to the exportin XPO1. 
Chemical name: (Z)-3-{3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl}-N’-(pyrazin-2-yl) 
acrylohydrazide 
Molecular formula: C17H11F6N7O 
Molecular weight: 443.31 
Dose Formulation 
ATG-010 will be supplied and administered in the form of 20 mg immediate-release coated tablet. 
Storage and Stability 
ATG-010 tablet (20 mg) will be supplied in plastic blister packs with aluminum foil lid and packed 
in children-resistant secondary cartons. ATG-010 should be stored in a locked safe area with access 
to study site pharmacists or designees, at a storage temperature ≤ 30°C (86°F). Room temperature 
storage is recommended, and refrigeration is allowed. Tablets shall not be frozen. 
Management 
The preparation, handling, and safe disposal of chemical drugs should be done in an independent 
protected environment by qualified personnel familiar with procedures for minimizing self and 
environmental overexposure. 
Availability 
ATG-010 is an investigational product that will be provided free of charge by Antengene. 
Preparation 
No special preparation is required ATG-010 tablet formulation shall not be crushed. 
Administration 
ATG-010 will be taken orally as tablet. ATG-010 should be swallowed with at least 120 mL of liquid 
(water, milk, juice, etc.) within 30 minutes after intake of solid food. 
Patients in this study will receive ATG-010 80 mg (45 mg/m2 BSA) plus dexamethasone (20 mg), 
twice weekly in four-week cycles. 
Accountability 
Investigator, or responsible party designated by Investigator must keep detailed records of drug 
inventory and disposal using the drug accountability record form or other similar drug accountability 
documents. 
Destruction and Recovery 
At the end of the study, unused ATG-010 supplies should be destroyed according to the policy of 
related institution. The destruction will be recorded in the drug accountability record form or other 
appropriate documents. 

 
ATG-010-MM-001 
Clinical Study Protocol 
 
 
Confidential 
02 Jan 2020, v4.0  
(02 Dec 2020 translated) 
 84/84 
 
 
Appendix 5. Products Containing Glutathione (GSH), S-adenosyl Methionine (SAM), or N-
acetylcysteine (NAC) (List of Representatives) 
Table 11:  Products Containing Glutathione (GSH), S-adenosyl Methionine (SAM), or N-
acetylcysteine (NAC) (List of Representatives) 
Glutathione (GSH) 
N-acetylcysteine (NAC) 
S-adenosyl Methionine 
(SAM) 
Product Name 
Ingredient 
Product Name 
Ingredient 
Product 
Name 
Ingredient 
Glutathione 
Glutathione 
Antidote to 
acetaminophen 
overdose 
Acetylcysteine 
SAM-e 
Complete 
S-adenosyl-
methionine 
L-glutathione 
L-glutathione 
Cerefolin NAC: 
medical food for age-
related memory loss 
L-methylfolate, 
Vitamin B12 
N-acetylcysteine 
SAMe 
S-adenosyl-
L-methionine 
Glutathione 
reduced  
Glutathione 
NAC 
N-acetylcysteine 
Double-
strength 
SAMe 400 
S-adenosyl-
methionine 
Reuced 
glutathione with 
α-lipoic Acid  
Setria L-
glutathione 
N-A-C Sustain 
N-acetyl-L-
cysteine 
 
 
Glutathione, 
cysteine & C 
Glutathione, L-
cysteine, 
Vitamin C 
Best NAC detox 
regulators 
N-acetylcysteine 
 
 
(Mega-) 
Liposomal 
Glutathione  
Glutathione 
 
 
 
 
Lypospheric GSH 
Glutathione 
 
 
 
 
Ivory Caps Skin 
Enhancement 
Formula 
Glutathione